##### Table of Contents





UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549





FORM 10-Q





(MARK ONE)

|x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|- | ---------------------------------------------------------------------------------------

FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2009

OR



| ̈ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|- | ----------------------------------------------------------------------------------------

FOR THE TRANSITION PERIOD FROM  TO

Commission
File Number 001-33719





MAP PHARMACEUTICALS, INC.

(Exact
name of registrant as specified in its charter)







|                                                               |  |                                     
|-------------------------------------------------------------- |  | ------------------------------------
|Delaware                                                       |  | 20-0507047                          
|(State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employer Identification No.)
|                                                               | 
|2400 Bayshore Parkway, Suite 200 Mountain View, California     |  | 94043                               
|(Address of principal executive offices)                       |  | (Zip code)                          

(650) 386-3100

(Registrants telephone number, including area code)

Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and
(2) has been subject to such filing requirements for the past 90 days.    Yes  x    No   ̈

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be
submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such
files).    Yes   ̈    No   ̈

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of large accelerated filer, accelerated filer
and smaller reporting company in Rule 12b-2 of the Exchange Act.



|                           |  |                      |  |                                               |  |                             
|-------------------------- |  | -------------------- |  | --------------------------------------------- |  | ----------------------------
|Large accelerated filer   ̈ |  | Accelerated filer  x |  | Non-accelerated filer   ̈                      |  | Smaller reporting company   ̈
|                           |  |                      |  | (Do not check if a smaller reporting company) |  |                             

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange
Act).    Yes   ̈    No  x

As of April 30, 2009, the registrant had outstanding 20,605,667 shares of Common Stock.









---

##### Table of Contents

TABLE OF CONTENTS



|                              |  |                                                                                                    |  |     
|----------------------------- |  | -------------------------------------------------------------------------------------------------- |  | ----
|                              |  |                                                                                                    |  | PAGE
|                              | 
|PART I. FINANCIAL INFORMATION |  | 3                                                                                                 
|                              |  |                                                                                                   
|Item 1.                       |  | Unaudited Condensed Consolidated Financial Statements                                              |  | 3   
|                              |  |                                                                                                   
|                              |  | Condensed Consolidated Balance Sheets as of March 31, 2009 and as of December 31, 2008             |  | 3   
|                              |  |                                                                                                   
|                              |  | Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2009 and 2008 |  | 4   
|                              |  |                                                                                                   
|                              |  | Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2009 and 2008 |  | 5   
|                              |  |                                                                                                   
|                              |  | Notes to Condensed Consolidated Financial Statements                                               |  | 6   
|                              |  |                                                                                                   
|Item 2.                       |  | Managements Discussion and Analysis of Financial Condition and Results of Operations              |  | 16  
|                              |  |                                                                                                   
|Item 3.                       |  | Quantitative and Qualitative Disclosures About Market Risk                                         |  | 23  
|                              |  |                                                                                                   
|Item 4.                       |  | Controls and Procedures                                                                            |  | 23  
|                              | 
|PART II. OTHER INFORMATION    |  | 24                                                                                                
|                              |  |                                                                                                   
|Item 1.                       |  | Legal Proceedings                                                                                  |  | 24  
|                              |  |                                                                                                   
|Item 1A.                      |  | Risk Factors                                                                                       |  | 24  
|                              |  |                                                                                                   
|Item 6.                       |  | Exhibits                                                                                           |  | 42  



2



---

##### Table of Contents

PART I FINANCIAL INFORMATION



|Item 1 | Financial Statements
|------ | --------------------

MAP PHARMACEUTICALS, INC.

(a development stage enterprise)

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

(Unaudited)



|                                                 |  |               |          |   |                  |   |          |  
|------------------------------------------------ |  | ------------- | -------- | - | ---------------- | - | -------- | -
|                                                 |  | March 31,2009 |          |   | December 31,2008 |  
|ASSETS                                           |  |               |          |   |                  |   |          |  
|Current assets:                                  |  |               |          |   |                  |   |          |  
|Cash and cash equivalents                        |  | $             | 67,705   |   |                  | $ | 31,927   |  
|Short-term investments                           |  |               |         |   |                  |   | 12,783   |  
|Accounts receivable                              |  |               | 4,725    |   |                  |   |         |  
|Prepaid expenses and other current assets        |  |               | 576      |   |                  |   | 805      |  
|                                                 |  |               |          |   |                  |   |          |  
|Total current assets                             |  |               | 73,006   |   |                  |   | 45,515   |  
|Property and equipment, net                      |  |               | 4,718    |   |                  |   | 5,007    |  
|Other assets                                     |  |               | 28       |   |                  |   | 28       |  
|Restricted investment                            |  |               | 310      |   |                  |   | 310      |  
|                                                 |  |               |          |   |                  |   |          |  
|Total assets                                     |  | $             | 78,062   |   |                  | $ | 50,860   |  
|                                                 |  |               |          |   |                  |   |          |  
|LIABILITIES AND STOCKHOLDERS EQUITY             |  |               |          |   |                  |   |          |  
|Current liabilities:                             |  |               |          |   |                  |   |          |  
|Accounts payable                                 |  | $             | 1,196    |   |                  | $ | 1,631    |  
|Accrued liabilities                              |  |               | 15,523   |   |                  |   | 15,445   |  
|Current portion of debt                          |  |               | 6,948    |   |                  |   | 6,348    |  
|Current portion of deferred revenue              |  |               | 16,552   |   |                  |   |         |  
|                                                 |  |               |          |   |                  |   |          |  
|Total current liabilities                        |  |               | 40,219   |   |                  |   | 23,424   |  
|Debt, less current portion                       |  |               | 12,585   |   |                  |   | 14,229   |  
|Deferred revenue, less current portion           |  |               | 20,690   |   |                  |   |         |  
|Other liabilities                                |  |               | 67       |   |                  |   | 60       |  
|                                                 |  |               |          |   |                  |   |          |  
|Total liabilities                                |  |               | 73,561   |   |                  |   | 37,713   |  
|                                                 |  |               |          |   |                  |   |          |  
|Commitments and contingencies (Note 6)           |  |               |          |   |                  |   |          |  
|Stockholders equity:                            |  |               |          |   |                  |   |          |  
|Common stock                                     |  |               | 200      |   |                  |   | 200      |  
|Additional paid-in capital                       |  |               | 190,115  |   |                  |   | 188,797  |  
|Deficit accumulated during the development stage |  |               | (185,814 | ) |                  |   | (175,894 | )
|Accumulated other comprehensive income           |  |               |         |   |                  |   | 44       |  
|                                                 |  |               |          |   |                  |   |          |  
|Total stockholders equity                       |  |               | 4,501    |   |                  |   | 13,147   |  
|                                                 |  |               |          |   |                  |   |          |  
|Total liabilities and stockholders equity       |  | $             | 78,062   |   |                  | $ | 50,860   |  
|                                                 |  |               |          |   |                  |   |          |  

The accompanying notes are an integral part of these condensed consolidated financial statements.



3



---

##### Table of Contents

MAP PHARMACEUTICALS, INC.

(a development stage enterprise)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except share and per share amounts)

(Unaudited)



|                                                                                                                                 |  |                              |            |   |                                                                     |   |            |   |  |   |          |  
|-------------------------------------------------------------------------------------------------------------------------------- |  | ---------------------------- | ---------- | - | ------------------------------------------------------------------- | - | ---------- | - |  | - | -------- | -
|                                                                                                                                 |  | Three Months Ended March 31, |            |   | CumulativePeriod fromJuly 3, 2003(Date ofInception) toMarch
31,2009 |  
|                                                                                                                                 |  | 2009                         |            |   | 2008                                                                |   |           
|Collaboration revenue                                                                                                            |  | $                            | 7,484      |   |                                                                     | $ |           |   |  | $ | 7,484    |  
|Operating expenses:                                                                                                              |  |                              |            |   |                                                                     |   |            |   |  |   |          |  
|Research and development                                                                                                         |  |                              | 14,075     |   |                                                                     |   | 11,815     |   |  |   | 145,773  |  
|Sales, general and administrative                                                                                                |  |                              | 2,808      |   |                                                                     |   | 3,140      |   |  |   | 36,870   |  
|                                                                                                                                 |  |                              |            |   |                                                                     |   |            |   |  |   |          |  
|Total operating expenses                                                                                                         |  |                              | 16,883     |   |                                                                     |   | 14,955     |   |  |   | 182,643  |  
|                                                                                                                                 |  |                              |            |   |                                                                     |   |            |   |  |   |          |  
|Loss from operations                                                                                                             |  |                              | (9,399     | ) |                                                                     |   | (14,955    | ) |  |   | (175,159 | )
|Interest income                                                                                                                  |  |                              | 85         |   |                                                                     |   | 853        |   |  |   | 6,334    |  
|Interest expense                                                                                                                 |  |                              | (602       | ) |                                                                     |   | (310       | ) |  |   | (4,235   | )
|Other income (expense), net                                                                                                      |  |                              | (4         | ) |                                                                     |   | 112        |   |  |   | (737     | )
|                                                                                                                                 |  |                              |            |   |                                                                     |   |            |   |  |   |          |  
|Net loss                                                                                                                         |  |                              | (9,920     | ) |                                                                     |   | (14,300    | ) |  |   | (173,797 | )
|                                                                                                                                 |  |                              |            |   |                                                                     |   |            |   |  |   |          |  
|Cumulative stock dividend attributed to preferred stockholders                                                                   |  |                              |           |   |                                                                     |   |           |   |  |   | (13,925  | )
|                                                                                                                                 |  |                              |            |   |                                                                     |   |            |   |  |   |          |  
|Net loss attributed to common stockholders                                                                                       |  | $                            | (9,920     | ) |                                                                     | $ | (14,300    | ) |  | $ | (187,722 | )
|                                                                                                                                 |  |                              |            |   |                                                                     |   |            |   |  |   |          |  
|Net loss per share attributed to common stockholders  basic and diluted                                                         |  | $                            | (0.48      | ) |                                                                     | $ | (0.71      | ) |  |   |          |  
|                                                                                                                                 |  |                              |            |   |                                                                     |   |            |   |  |   |          |  
|Weighted average shares outstanding used in calculating net loss per share attributed to common stockholders  basic and
diluted |  |                              | 20,583,774 |   |                                                                     |   | 20,209,739 |   |  |   |          |  
|                                                                                                                                 |  |                              |            |   |                                                                     |   |            |   |  |   |          |  

The accompanying notes are an integral part of these condensed consolidated financial statements.



4



---

##### Table of Contents

MAP PHARMACEUTICALS, INC.

(a development stage enterprise)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)



|                                                                                          |  |                              |        |   |                                                                       |   |         |   |  |   |          |  
|----------------------------------------------------------------------------------------- |  | ---------------------------- | ------ | - | --------------------------------------------------------------------- | - | ------- | - |  | - | -------- | -
|                                                                                          |  | Three Months Ended March 31, |        |   | Cumulative Periodfrom July 3, 2003(Date ofInception) toMarch 31, 2009 |  
|                                                                                          |  | 2009                         |        |   | 2008                                                                  |   |         |   | 
|Cash flows from operating activities:                                                     |  |                              |        |   |                                                                       |   |         |   |  |   |          |  
|Net loss                                                                                  |  | $                            | (9,920 | ) |                                                                       | $ | (14,300 | ) |  | $ | (173,797 | )
|Adjustments to reconcile net loss to net cash provided by (used in) operating activities: |  |                              |        |   |                                                                       |   |         |   |  |   |          |  
|Depreciation and amortization                                                             |  |                              | 375    |   |                                                                       |   | 230     |   |  |   | 3,555    |  
|Accretion of investment discounts, net                                                    |  |                              | (1     | ) |                                                                       |   | (343    | ) |  |   | (1,595   | )
|Amortization of debt issuance costs                                                       |  |                              |       |   |                                                                       |   | 23      |   |  |   | 210      |  
|Accretion of debt payment premium                                                         |  |                              | 110    |   |                                                                       |   |        |   |  |   | 410      |  
|Change in carrying value of warrant liability                                             |  |                              |       |   |                                                                       |   |        |   |  |   | 621      |  
|Issuance of common stock in exchange for services                                         |  |                              |       |   |                                                                       |   |        |   |  |   | 51       |  
|Share-based compensation                                                                  |  |                              | 1,269  |   |                                                                       |   | 837     |   |  |   | 7,623    |  
|Loss on disposal and other non-cash items                                                 |  |                              | 16     |   |                                                                       |   |        |   |  |   | 400      |  
|Changes in operating assets and liabilities:                                              |  |                              |        |   |                                                                       |   |         |   |  |   |          |  
|Accounts receivable                                                                       |  |                              | (4,725 | ) |                                                                       |   |        |   |  |   | (4,725   | )
|Prepaid expenses and other current assets                                                 |  |                              | 229    |   |                                                                       |   | 221     |   |  |   | (801     | )
|Other assets                                                                              |  |                              |       |   |                                                                       |   |        |   |  |   | 65       |  
|Accounts payable                                                                          |  |                              | (435   | ) |                                                                       |   | (356    | ) |  |   | 1,167    |  
|Accrued liabilities                                                                       |  |                              | 78     |   |                                                                       |   | 746     |   |  |   | 15,492   |  
|Deferred revenue                                                                          |  |                              | 37,242 |   |                                                                       |   |        |   |  |   | 37,242   |  
|Other liabilities                                                                         |  |                              | 7      |   |                                                                       |   |        |   |  |   | 67       |  
|                                                                                          |  |                              |        |   |                                                                       |   |         |   |  |   |          |  
|Net cash provided by (used in) operating activities                                       |  |                              | 24,245 |   |                                                                       |   | (12,942 | ) |  |   | (114,015 | )
|                                                                                          |  |                              |        |   |                                                                       |   |         |   |  |   |          |  
|Cash flows from investing activities:                                                     |  |                              |        |   |                                                                       |   |         |   |  |   |          |  
|Purchase of intangible assets and in-process research and development                     |  |                              |       |   |                                                                       |   |        |   |  |   | (412     | )
|Purchase of property and equipment                                                        |  |                              | (102   | ) |                                                                       |   | (590    | ) |  |   | (8,227   | )
|Purchase of short-term investments                                                        |  |                              |       |   |                                                                       |   | (28,986 | ) |  |   | (169,497 | )
|Sales and maturities of short-term investments                                            |  |                              | 12,740 |   |                                                                       |   | 26,477  |   |  |   | 171,411  |  
|Purchase of restricted investment                                                         |  |                              |       |   |                                                                       |   |        |   |  |   | (310     | )
|                                                                                          |  |                              |        |   |                                                                       |   |         |   |  |   |          |  
|Net cash provided by (used in) investing activities                                       |  |                              | 12,638 |   |                                                                       |   | (3,099  | ) |  |   | (7,035   | )
|                                                                                          |  |                              |        |   |                                                                       |   |         |   |  |   |          |  
|Cash flows from financing activities:                                                     |  |                              |        |   |                                                                       |   |         |   |  |   |          |  
|Proceeds from issuance of convertible notes payable                                       |  |                              |       |   |                                                                       |   |        |   |  |   | 4,300    |  
|Proceeds from issuance of debt                                                            |  |                              |       |   |                                                                       |   |        |   |  |   | 31,006   |  
|Proceeds from sales of shares through equity plans                                        |  |                              | 49     |   |                                                                       |   | 34      |   |  |   | 836      |  
|Repayment of debt                                                                         |  |                              | (1,154 | ) |                                                                       |   | (762    | ) |  |   | (11,983  | )
|Proceeds from issuance of common stock in IPO, net of issuance costs                      |  |                              |       |   |                                                                       |   |        |   |  |   | 62,168   |  
|Proceeds from issuance of convertible preferred stock, net of issuance costs              |  |                              |       |   |                                                                       |   |        |   |  |   | 102,428  |  
|                                                                                          |  |                              |        |   |                                                                       |   |         |   |  |   |          |  
|Net cash provided by (used in) financing activities                                       |  |                              | (1,105 | ) |                                                                       |   | (728    | ) |  |   | 188,755  |  
|                                                                                          |  |                              |        |   |                                                                       |   |         |   |  |   |          |  
|Net increase (decrease) in cash and cash equivalents                                      |  |                              | 35,778 |   |                                                                       |   | (16,769 | ) |  |   | 67,705   |  
|Cash and cash equivalents at beginning of period                                          |  |                              | 31,927 |   |                                                                       |   | 49,116  |   |  |   |         |  
|                                                                                          |  |                              |        |   |                                                                       |   |         |   |  |   |          |  
|Cash and cash equivalents at end of period                                                |  | $                            | 67,705 |   |                                                                       | $ | 32,347  |   |  | $ | 67,705   |  
|                                                                                          |  |                              |        |   |                                                                       |   |         |   |  |   |          |  
|Supplemental disclosures of cash flow information                                         |  |                              |        |   |                                                                       |   |         |   |  |   |          |  
|Cash paid for interest                                                                    |  | $                            | 499    |   |                                                                       | $ | 294     |   |  | $ | 3,521    |  

The accompanying notes are an integral part of these condensed consolidated financial statements.



5



---

##### Table of Contents

MAP PHARMACEUTICALS, INC.

(a development stage enterprise)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 1. THE COMPANY

MAP Pharmaceuticals, Inc.,
incorporated in the state of Delaware, was originally formed as a limited liability company on July 3, 2003 and converted to a corporation on December 11, 2003. We use proprietary inhalation technologies to enhance the therapeutic benefits
and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. We have several proprietary product candidates in clinical development that address large market
opportunities, including our two most advanced product candidates: a proprietary formulation of nebulized budesonide for the potential treatment of asthma in children from 12 months to eight years of age; and a proprietary orally inhaled version of
dihydroergotamine for the potential treatment of migraine. We are in the development stage and since inception have devoted substantially all of our efforts to research and development, raising capital and recruiting personnel.

We have incurred losses and negative cash flow since our inception in July 2003. We will continue to be in a loss position until sufficient revenue can
be generated to offset our expenses, and we anticipate that we will continue to incur net losses for the next several years. We expect that our research and development and sales, general and administrative expenses may continue to increase and, as
a result, we will need to generate significant net product sales, royalty and other revenues to achieve profitability. Prior to achieving profitable operations, we intend to continue to fund operations through public or private financings, strategic
partnerships or other arrangements. Such funding, if needed, may not be available on favorable terms, if at all. In the event we are unable to obtain additional capital, we may delay or reduce the scope of our current research and development
programs and other expenses.

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

We have
prepared the accompanying interim condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of
Regulation S-X. Accordingly, these financial statements and accompanying notes do not include all of the information and disclosures required by generally accepted accounting principles for complete financial statements. The financial statements
include all adjustments (consisting of normal recurring adjustments) that management believes are necessary for the fair statement of the balances and results for the periods presented. These interim financial statement results are not necessarily
indicative of the results to be expected for the full fiscal year or any future interim period.

The balance sheet at December 31,
2008 has been derived from the audited financial statements at that date. The financial statements and related disclosures have been prepared with the presumption that users of the interim financial statements have read or have access to the audited
financial statements for the preceding fiscal year. Accordingly, these financial statements should be read in conjunction with the audited financial statements and notes thereto contained in our Form 10-K for the year ended December 31, 2008,
as amended.

Revenue Recognition

We recognize revenue in accordance with SEC Staff Accounting Bulletin, or SAB, No. 104, Revenue Recognition. SAB No. 104 requires that certain criteria must be met before revenue can be
recognized: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; the fee is fixed or determinable; and collectability is reasonably assured. Determination of whether persuasive evidence of an
arrangement exists and whether delivery has occurred or services have been rendered are based on managements judgments regarding the fixed nature of the fee charged for research performed and milestones met, and the collectability of those
fees. Should changes in conditions cause management to determine these criteria are not met for certain future transactions, revenue recognized for any reporting period could be adversely affected.

Collaboration revenue, which is earned under agreements with third parties for research and development activities, may include nonrefundable license
fees, cost reimbursements and contingent milestones and royalties. Our revenue arrangements with multiple elements are evaluated under Emerging Issues Task Force, or EITF, Issue No. 00-21, Revenue Arrangements with Multiple Deliverables,
and are divided into separate units of accounting if certain criteria are met, including whether the delivered element has stand-alone value and whether there is objective and reliable evidence of the fair value of the undelivered items. The
consideration we receive is allocated among the separate units based on their respective fair values, and the applicable revenue recognition criteria are applied to each of the separate units.



6



---

##### Table of Contents

Upfront payments received upon execution of collaborative agreements are recorded as deferred revenue and
recognized as collaboration revenue over the research and development period pursuant to the agreement. Such period generally represents the research and development period set forth in the agreement between our third party collaborator and us. The
research and development period is estimated at the inception of the arrangement and is periodically reevaluated. Reevaluation of the research and development period may shorten or lengthen the period during which the deferred revenue is recognized.
We evaluate the appropriate period based on research progress attained and reevaluate the period when significant changes occur.

Cost
reimbursements are based upon negotiated rates for our full time employee equivalents, or FTE, and actual out-of-pocket costs. They are recognized as collaboration revenue as the related research and development services are performed. The cost
reimbursements are generally based on qualified expenses as defined in the collaborative agreement. FTE rates are intended to approximate our anticipated cost.

We recognize milestone payments as revenue upon achievement of the milestone provided the milestone payment is nonrefundable, substantive effort and risk is involved in achieving the milestone and the amount of the
milestone is reasonable in relation to the effort expended or risk associated with the achievement of the milestone. If these conditions are not met, we defer the milestone payment and recognize it as revenue over the estimated period of performance
under the contract as we complete our performance obligations.

Pre-clinical Study and Clinical Trial Accruals

We estimate our pre-clinical study and clinical trial expenses based on the services received pursuant to contracts with several research institutions and
contract research organizations that conduct and manage pre-clinical studies and clinical trials on our behalf. The financial terms of these agreements vary from contract to contract and may result in uneven expenses and payment flows. Pre-clinical
study and clinical trial expenses include the following:



| |  |  | fees paid to contract research organizations in connection with pre-clinical studies;
| | - |  | -------------------------------------------------------------------------------------



| |  |  | fees paid to contract research organizations and investigative sites in connection with clinical trials; and
| | - |  | ------------------------------------------------------------------------------------------------------------



| |  |  | fees paid to contract manufacturers and service providers in connection with the production and testing of active pharmaceutical ingredients and drug materials for
use in pre-clinical studies and clinical trials.
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Payments under some of these contracts depend on factors such as the
milestones accomplished, successful enrollment of certain number of patients, site initiation and completion of clinical trial milestones. In accruing services fees, we estimate the time period over which services will be performed and the level of
effort to be expended in each period. We monitor patient enrollment levels and related activities to the extent possible through internal reviews, correspondence and status meetings with CROs and review of contractual terms. Our estimates are
dependent on the timeliness and accuracy of data provided by our CROs and other vendors. If we have incomplete or inaccurate information, we may underestimate or overestimate activity levels associated with various studies or clinical trials at a
given point in time. In this event, we could record adjustments to research and development expenses in future periods when the actual activity levels become known.

Share-Based Compensation

Effective January 1, 2006, we adopted SFAS No. 123
(revised 2004), Share-Based Payment, using the prospective transition method, which requires the measurement and recognition of compensation expense for all share-based payment awards granted, modified and settled to our employees and
directors after January 1, 2006. Our financial statements reflect the impact of SFAS No. 123(R). We chose the straight-line attribution method for allocating compensation costs and recognized the fair value of each stock option
on a straight-line basis over the requisite service period.

We account for equity instruments issued to non-employees in accordance with
the provisions of SFAS No. 123, Accounting for Stock-Based Compensation and EITF, No. 96-18, Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services.
Equity instruments issued to non-employees are recorded at their fair value on the measurement date and are subject to periodic adjustment as the underlying equity instruments vest.

Fair Value of Financial Instruments

The carrying amounts of certain of our financial instruments including cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their short maturities.

Comprehensive loss

We report comprehensive income (loss) in accordance with SFAS No. 130, Reporting Comprehensive Income. Components of other comprehensive income (loss), including unrealized gains (losses) on our available-for-sale securities,
are included in total comprehensive loss.



7



---

##### Table of Contents

|                                                                |  |                              |        |   |      |   |         |  
|--------------------------------------------------------------- |  | ---------------------------- | ------ | - | ---- | - | ------- | -
|                                                                |  | Three Months Ended March 31, |       
|                                                                |  | 2009                         |        |   | 2008 |  
|Net loss                                                        |  | $                            | (9,920 | ) |      | $ | (14,300 | )
|Net change in unrealized loss on available-for-sale investments |  |                              | (44    | ) |      |   | (2      | )
|                                                                |  |                              |        |   |      |   |         |  
|Comprehensive loss                                              |  | $                            | (9,964 | ) |      | $ | (14,302 | )
|                                                                |  |                              |        |   |      |   |         |  

Net Loss per Share

Basic net loss per share is computed by dividing net loss attributed to common stockholders by the weighted average number of common shares outstanding
during the period. Our potential dilutive shares, which include outstanding common stock options, unvested common shares subject to repurchase and warrants, have not been included in the computation of diluted net loss per share for all the periods
as the result would be anti-dilutive. Such potentially dilutive shares are excluded when the effect would be to reduce a net loss per share.

A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share follows (in thousands, except share and per share amounts):



|                                                     |  |                              |            |   |      |   |            |  
|---------------------------------------------------- |  | ---------------------------- | ---------- | - | ---- | - | ---------- | -
|                                                     |  | Three Months Ended March 31, |           
|                                                     |  | 2009                         |            |   | 2008 |  
|Numerator                                            |  |                              |            |   |      |   |            |  
|Net loss attributed to common stockholders           |  | $                            | (9,920     | ) |      | $ | (14,300    | )
|                                                     |  |                              |            |   |      |   |            |  
|Denominator                                          |  |                              |            |   |      |   |            |  
|Weighted average common shares outstanding           |  |                              | 20,583,774 |   |      |   | 20,235,773 |  
|Less: weighted average shares subject to repurchase  |  |                              |           |   |      |   | (26,034    | )
|                                                     |  |                              |            |   |      |   |            |  
|Denominator for basic and diluted net loss per share |  |                              | 20,583,774 |   |      |   | 20,209,739 |  
|                                                     |  |                              |            |   |      |   |            |  
|Basic and diluted net loss per share                 |  | $                            | (0.48      | ) |      | $ | (0.71      | )
|                                                     |  |                              |            |   |      |   |            |  

The following outstanding options, common stock subject to repurchase and warrants were excluded
from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect:



|                                   |  |                              |  |          
|---------------------------------- |  | ---------------------------- |  | ---------
|                                   |  | Three Months Ended March 31,
|                                   |  | 2009                         |  | 2008     
|Options to purchase common stock   |  | 4,028,503                    |  | 3,148,879
|Common stock subject to repurchase |  |                             |  | 21,695   
|Warrants                           |  | 73,989                       |  | 73,989   

Recent Accounting Pronouncements

In April 2009, the FASB issued FASB Staff Position, or FSP, FAS 157-4, Determining Fair Value When the Volume and Level of Activity for the Asset or
Liability Have Significantly Decreased and Identifying Transactions That Are Not Orderly. FSP FAS 157-4 provides guidelines for making fair value measurements more consistent with the principles presented in FASB Statement No. 157, Fair
Value Measurements. FSP FAS 157-4 relates to determining fair values when there is no active market or where the price inputs being used represent distressed sales. It reaffirms what Statement 157 states is the objective of fair value
measurementto reflect how much an asset would be sold for in an orderly transaction (as opposed to a distressed or forced transaction) at the date of the financial statements under current market conditions. Specifically, it reaffirms the need
to use judgment to ascertain if a formerly active market has become inactive and in determining fair values when markets have become inactive. FSP FAS 157-4 is effective for interim and annual periods ending after June 15, 2009. As a result, it
is effective for us in the second quarter of fiscal 2009. We do not believe that the adoption of FSP FAS 157-4 will have a material impact on our financial statements.

In April 2009, the FASB issued FSP FAS 107-1 and APB 28-1, Interim Disclosures about Fair Value of Financial Instruments. FSP FAS 107-1 and APB 28-1 enhance consistency in financial reporting by increasing the
frequency of fair value disclosures. FSP FAS 107-1 and APB 28-1 relate to fair value disclosures for any financial instruments that are not currently reflected on the balance sheet of companies at fair value. Prior to issuing this FSP, fair values
for these assets and liabilities were disclosed only once a year. The FSP now requires these disclosures to be made on a quarterly basis, providing qualitative and quantitative information about fair value estimates for all those financial
instruments not measured on the balance sheet at fair value. FSP FAS 107-1 and APB 28-1 are effective for interim and annual periods ending after June 15, 2009. As a result, they are effective for us in the second quarter of fiscal 2009. We do
not believe that the adoption of FSP FAS 107-1 and APB 28-1 will have a material impact on our financial statements.



8



---

##### Table of Contents

NOTE 3. LICENSE AND SUPPLY AGREEMENTS

Agreement with AstraZeneca

In
December 2008, we entered into a license agreement with AstraZeneca AB, or AstraZeneca Agreement, which became effective in February 2009. Pursuant to the terms of the agreement, we licensed to AstraZeneca global rights to develop and commercialize
our proprietary nebulized formulation of Unit Dose Budesonide, or UDB, our next generation UDB therapy and certain combination nebulization therapies for the potential treatment of asthma in children.

We are jointly developing UDB in the United States with AstraZeneca, and we are responsible for executing the development plan. AstraZeneca reimburses us
for the costs of future UDB development activities beginning on the effective date, and has the right to develop follow-on products using different nebulizers and certain products combining nebulized budesonide with other drugs. AstraZeneca has
rights to commercialize UDB in the United States and to develop and commercialize UDB outside of the United States.

AstraZeneca will pay
for up to a 60-person sales force for the company to co-promote UDB with AstraZeneca in the United States after product launch. AstraZeneca will provide funding for this sales force for up to five years after product launch.

In February 2009, under the terms of this agreement, AstraZeneca paid us a nonrefundable upfront cash payment of $40 million. The agreement also provided for a $35
million milestone payment payable upon the successful achievement of co-primary endpoints and safety results in our initial Phase 3 clinical trial. In addition, we are eligible to receive up to $240 million in other development and regulatory
milestones. The agreement also provides for additional progressively demanding sales performance-related milestone payments of up to $585 million in the event the product is a considerable commercial success.

We are also eligible to receive significant and escalating double-digit royalty payments on worldwide sales, as well as reimbursement for all royalties
payable to Elan Pharma International Limited, or Elan, under our license agreement with Elan. These payments will begin following the date of the first commercial sale of UDB or any other licensed product. We are also eligible to receive
reimbursement for a portion of certain milestone payments payable to Elan. Under the terms of the agreement, both companies agree, under certain circumstances, for a period until three years after the first commercial sale of a licensed product in
the United States, not to commercialize or assist any third party in commercializing certain competing products. We also have the right to terminate the agreement in relation to licensed products developed for administration solely using jet
nebulizers if AstraZeneca commercializes certain competing products for use in jet nebulizers.

Either party may terminate the AstraZeneca
Agreement upon a material, uncured default of the other party. AstraZeneca may terminate the agreement, with or without cause, at any time upon 90 days prior written notice. If AstraZeneca terminates the agreement under certain circumstances,
AstraZeneca will be obligated to reimburse our remaining development costs under the development plan. Our failure to meet co-primary endpoints in our initial Phase 3 clinical trial, gives AstraZeneca the right to terminate the agreement, or
continue with the collaboration without paying the $35 million milestone. AstraZeneca has 60 days from deemed receipt of the complete data package from our initial Phase 3 clinical trial to decide whether to terminate the agreement. If AstraZeneca
proceeds with the collaboration, AstraZeneca will be responsible for reimbursing the remaining development costs we incur under the development plan.

On February 23, 2009, we announced top-line results of our initial Phase 3 clinical trial of UDB for the potential treatment of children with asthma. We announced that the clinical trial did not meet its
co-primary endpoints, asthma control as assessed by changes from baseline in nighttime and daytime composite symptom scores, in either of the doses evaluated when compared with placebo.

For the three months ended March 31, 2009, we recognized $7.5 million of collaboration revenue from AstraZeneca including amortization of the
nonrefundable upfront payment of $40.0 million and reimbursement of qualified development expenses. The $40.0 million upfront payment is recognized as collaboration revenue on a straight-line basis over the term of our research and development
period with respect to UDB.

Agreement with Nektar

Under the June 2004 agreement, as amended, with Nektar Therapeutics UK Limited, or Nektar Agreement, we were granted a worldwide, exclusive license,
with a right to sublicense, under Nektar patents and know-how, to develop and commercialize any formulation of a form of dihydroergotamine for administration by inhalation using a device. We also agreed to pay royalties at specified rates based on
net sales. As of March 31, 2009, we are required to make future nonrefundable milestone payments of up to $5.0 million related to products currently being developed under this agreement, when and if certain regulatory and commercial milestones
are met. We paid $0, $0 and $2.6 million related to milestones under the Nektar Agreement for the three months ended March 31, 2009 and 2008 and for the cumulative period from July 3, 2003 (date of inception) to March 31, 2009,
respectively. Either party may terminate the Nektar Agreement upon a material, uncured default of the other party. We may terminate the agreement, with or without cause, at any time upon six months prior written notice.



9



---

##### Table of Contents

Agreement with Elan

Under the April 2004 agreement, as amended, with Elan Pharma International Limited, or Elan Agreement, Elan granted to us a worldwide, exclusive,
sub-licensable license under Elans intellectual property rights to use, market, distribute, sell, have sold, offer for sale, import and export certain ingredients for our UDB product candidate. We also agreed to pay royalties at specified
rates based on net sales. As of March 31, 2009, we are required to make future nonrefundable milestone payments of up to $16.5 million related to products currently being developed under this agreement, when and if certain regulatory and
commercial milestones under the Elan Agreement are met with respect to our UDB product candidate. We paid $0, $0.8 million and $4.0 million related to milestones for the three months ended March 31, 2009 and 2008 and for the cumulative period
from July 3, 2003 (date of inception) to March 31, 2009, respectively. Either party may terminate the Elan Agreement upon a material, uncured default of the other party. We may terminate the agreement, with or without cause, at any time
upon 90 days prior written notice. We also entered into a services agreement with Elan Drug Delivery International in February 2005. In connection with the execution of the license agreement with AstraZeneca, we amended the Elan agreements,
pursuant to which AstraZeneca has certain rights to exercise and enforce certain of our rights with Elan prior to the expiration or termination of the AstraZeneca Agreement. The amendments did not impact our unaudited condensed consolidated
financial statements.

NOTE 4. FAIR VALUE MEASUREMENTS

On January 1, 2008, we adopted SFAS, No. 157, Fair Value Measurements,or SFAS 157, as it relates to financial assets and financial liabilities. In February 2008, the FASB issued FSP FAS 157-2,
Effective Date of FASB Statement No. 157, which delayed the effective date of SFAS 157 for all nonfinancial assets and nonfinancial liabilities, except those that are recognized or disclosed at fair value in the financial statements on
at least an annual basis, until January 1, 2009 for calendar year-end entities. SFAS 157 defines fair value, establishes a framework for measuring fair value in GAAP and expands disclosures about fair value measurements.

SFAS 157 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market
participants at the measurement date. This standard is now the single source in GAAP for the definition of fair value, except for the fair value of leased property as defined in SFAS No. 13, Accounting for Leases. SFAS 157 establishes a fair
value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entitys own assumptions about market participant
assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for
identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under SFAS 157 are described below:



| |  |  | Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the
highest priority to Level 1 inputs.
| | - |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | Level 2: Directly or indirectly observable inputs as of the reporting date through correlation with market data, including quoted prices for similar assets and
liabilities in active markets and quoted prices in markets that are not active. Level 2 also includes assets and liabilities that are valued using models or other pricing methodologies that do not require significant judgment since the input
assumptions used in the models, such as interest rates and volatility factors, are corroborated by readily observable data from actively quoted markets for substantially the full term of the financial instrument.
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | Level 3: Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment. These values are generally
determined using pricing models for which the assumptions utilize managements estimates of market participant assumptions.
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

In determining fair value, we utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in our assessment of
fair value.



10



---

##### Table of Contents

The following is a summary of our cash, cash equivalents and available-for-sale securities as of
March 31, 2009 and December 31, 2008, respectively (in thousands):



|                                            |  |                       |        |                         |   |    |  |   |       
|------------------------------------------- |  | --------------------- | ------ | ----------------------- | - | -- |  | - | ------
|                                            |  | AmortizedCost         |        | As of March 31, 2009   
|                                            |  | Unrealized Gain(Loss) |        | Estimated FairValue    
|Cash                                        |  | $                     | 3,585  |                         | $ |   |  | $ | 3,585 
|Certificates of deposit                     |  |                       | 310    |                         |   |   |  |   | 310   
|Money market funds                          |  |                       | 64,120 |                         |   |   |  |   | 64,120
|                                            |  |                       |        |                         |   |    |  |   |       
|                                            |  | $                     | 68,015 |                         | $ |   |  | $ | 68,015
|                                            |  |                       |        |                         |   |    |  |   |       
|Reported as:                                |  |                       |        |                         |   |    |  |   |       
|Cash and cash equivalents                   |  |                       |        |                         |   |    |  | $ | 67,705
|Restricted investment                       |  |                       |        |                         |   |    |  |   | 310   
|                                            |  |                       |        |                         |   |    |  |   |       
|                                            |  |                       |        |                         |   |    |  | $ | 68,015
|                                            |  |                       |        |                         |   |    |  |   |       
|                                            |  |                      
|                                            |  | AmortizedCost         |        | As of December 31, 2008
|                                            |  | Unrealized Gain(Loss) |        | Estimated FairValue    
|Cash                                        |  | $                     | 3,021  |                         | $ |   |  | $ | 3,021 
|Certificates of deposit                     |  |                       | 310    |                         |   |   |  |   | 310   
|Money market funds                          |  |                       | 27,895 |                         |   |   |  |   | 27,895
|Corporate debt securities                   |  |                       | 2,684  |                         |   | 6  |  |   | 2,690 
|U.S. government and its agencies securities |  |                       | 11,066 |                         |   | 38 |  |   | 11,104
|                                            |  |                       |        |                         |   |    |  |   |       
|                                            |  | $                     | 44,976 |                         | $ | 44 |  | $ | 45,020
|                                            |  |                       |        |                         |   |    |  |   |       
|Reported as:                                |  |                       |        |                         |   |    |  |   |       
|Cash and cash equivalents                   |  |                       |        |                         |   |    |  | $ | 31,927
|Short-term investments                      |  |                       |        |                         |   |    |  |   | 12,783
|Restricted investment                       |  |                       |        |                         |   |    |  |   | 310   
|                                            |  |                       |        |                         |   |    |  |   |       
|                                            |  |                       |        |                         |   |    |  | $ | 45,020
|                                            |  |                       |        |                         |   |    |  |   |       

Our investment instruments are classified within Level 1 or Level 2 of the fair value
hierarchy because they are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. The types of instruments that are generally classified within Level 1 of the fair
value hierarchy include money market securities. The types of investments that are generally classified within Level 2 of the fair value hierarchy include U.S. government and agency securities, corporate debt securities and certificates of deposit.

As of March 31, 2009, financial assets measured and recognized at fair value on a recurring basis and classified under the
appropriate level of the fair value hierarchy as described above was as follows (in thousands):



|                        |  |         |        |         |   |         |  |       |   |  |   |       
|----------------------- |  | ------- | ------ | ------- | - | ------- |  | ----- | - |  | - | ------
|                        |  | Level 1 |        | Level 2 |   | Level 3 |  | Total
|Certificates of Deposit |  | $       |       |         | $ | 310     |  | $     |  |  | $ | 310   
|Money Market Funds      |  |         | 64,120 |         |   |        |  |       |  |  |   | 64,120
|                        |  |         |        |         |   |         |  |       |   |  |   |       
|Total                   |  | $       | 64,120 |         | $ | 310     |  | $     |  |  | $ | 64,430
|                        |  |         |        |         |   |         |  |       |   |  |   |       

Our investments in money market funds are measured at fair value on a recurring basis. Our money
market funds comply with Rule 2a-7 of the Investment Company Act of 1940 and are required to be priced and have a fair value of $1 net asset value per share. These money market funds are actively traded and reported daily through a variety of
sources. Due to the structure and valuation required by the Investment Company Act of 1940 regarding Rule 2a-7 funds, the fair value of the money market fund investments is classified as Level 1.

The fair value of the Certificates of Deposit is classified as Level 2 due to the nature of a contractual restriction related to our lease agreements.



11



---

##### Table of Contents

The carrying amount reported in the consolidated balance sheet as of March 31, 2009 for our debt is
$19.5 million. Using a discounted cash flow technique that incorporates a market interest rate, we have determined the fair value of our debt to be $18.6 million at March 31, 2009.

NOTE 5. BALANCE SHEET COMPONENTS

Accrued liabilities

Accrued liabilities consist of the following (in thousands):



|                                |  |               |        |                  |   |       
|------------------------------- |  | ------------- | ------ | ---------------- | - | ------
|                                |  | March 31,2009 |        | December 31,2008
|Clinical trial related          |  | $             | 12,332 |                  | $ | 11,329
|Payroll and related expenses    |  |               | 1,878  |                  |   | 2,791 
|Professional services and other |  |               | 1,313  |                  |   | 1,325 
|                                |  |               |        |                  |   |       
|                                |  | $             | 15,523 |                  | $ | 15,445
|                                |  |               |        |                  |   |       

Debt

In September 2006, we entered into a $3.0 million loan facility agreement for the purpose of financing equipment purchases, or Equipment Loan, and borrowed $1.0 million under this facility. The Equipment Loan bears
interest at an annual interest rate of 9.5% and matures in 2009.

In September 2006, we entered into a $10.0 million loan facility
agreement for the purpose of financing working capital, or 2006 Working Capital Loan, and borrowed all $10.0 million under the facility agreement during the year ended December 31, 2006. The 2006 Working Capital Loan bears interest at an annual
interest rate of 11.9% and matures in 2010. In May 2008, we entered into a new loan agreement, or 2008 Working Capital Loan, for $20.0 million in order to repay the 2006 Working Capital Loan and to support general corporate purposes. The 2008
Working Capital Loan bears interest at an annual rate of 9.95%, with an effective rate of approximately 12% after factoring in a $1.0 million payment due at the termination of the agreement. The 2008 Working Capital Loan has interest-only payments
up to and including January 2009, maturing in October 2011, and includes customary loan covenants. As of March 31, 2009, we were in compliance with the loan covenants. Expenses incurred in connection with the new loan agreement were not
material.

The 2008 Working Capital Loan amounts are collateralized by all of our assets, excluding intellectual property, while Equipment
Loan amounts are collateralized by our equipment purchased by such borrowed funds.

Our debt consisted of the following (in thousands):



|                                                     |  |               |        |                  |   |       
|---------------------------------------------------- |  | ------------- | ------ | ---------------- | - | ------
|                                                     |  | March 31,2009 |        | December 31,2008
|Principal amount                                     |  | $             | 19,123 |                  | $ | 20,277
|Plus: premium, based on imputed interest rate of 12% |  |               | 410    |                  |   | 300   
|                                                     |  |               |        |                  |   |       
|                                                     |  |               | 19,533 |                  |   | 20,577
|Less: current portion of debt                        |  |               | 6,948  |                  |   | 6,348 
|                                                     |  |               |        |                  |   |       
|Long-term portion                                    |  | $             | 12,585 |                  | $ | 14,229
|                                                     |  |               |        |                  |   |       

As of March 31, 2009, debt payments, which include interest and principal, are as follows (in
thousands):



|                             |  |        |       
|---------------------------- |  | ------ | ------
|Year ending December 31,     |  | Amount
|2009 (remaining nine months) |  | $      | 6,449 
|2010                         |  |        | 8,343 
|2011                         |  |        | 7,952 
|                             |  |        |       
|Total debt payments          |  | $      | 22,744
|                             |  |        |       



12



---

##### Table of Contents

NOTE 6. COMMITMENTS AND CONTINGENCIES

Operating Leases

In
June 2004, we entered into a lease agreement for laboratory and office facilities in Mountain View, California and in August 2006 amended our lease agreement to include additional square footage within the same building. In March 2008, we
further amended our lease agreement, or March 2008 Amendment, to extend the term of the agreement until June 2012, and to include additional square footage and options to lease additional square footage. In September 2008, we amended and restated
the March 2008 Amendment to the lease agreement, providing for expanded square footage and certain renewal options. The facility lease requires us to pay operating costs, including property taxes, insurance and maintenance in addition to monthly
rent. Rent is subject to an annual increase for the duration of the lease, which we recognize on a straight-line basis. The annual lease payments for the space leased under the amended and restated lease agreement were effective as of July 1,
2008.

Rent expense was approximately $0.3 million, $0.2 million and $3.7 million for the three months ended March 31, 2009 and 2008
and for the cumulative period from July 3, 2003 (date of inception) to March 31, 2009, respectively.

As of March 31, 2009,
future minimum lease payments are as follows (in thousands):



|                             |  |        |      
|---------------------------- |  | ------ | -----
|Year ending December 31,     |  | Amount
|2009 (remaining nine months) |  | $      | 787  
|2010                         |  |        | 1,293
|2011                         |  |        | 1,357
|2012                         |  |        | 700  
|                             |  |        |      
|Total minimum lease payments |  | $      | 4,137
|                             |  |        |      

In accordance with the terms of the lease agreements we are obligated to maintain an irrevocable
letter of credit from a bank as a security deposit. As collateral for the letter of credit, we are required to maintain a deposit account with the bank of $0.3 million at March 31, 2009 and December 31, 2008, which is shown as a restricted
investment on our unaudited condensed consolidated balance sheets.

Contingencies

We are subject to claims and assessments from time to time in the ordinary course of business. We do not believe that any such matters, individually or in
the aggregate, will have a material adverse effect on our financial condition or results of operation.

Indemnification

In the normal course of business, we enter into contracts and agreements that contain a variety of representations and warranties
and provide for general indemnifications. Our exposure under these agreements is unknown because it involves claims that may be made against us in the future, but have not yet been made. To date, we have not paid any claims or been required to
defend any action related to our indemnification obligations. However, we may record charges in the future as a result of these indemnification obligations.

In accordance with our certificate of incorporation and bylaws, we have indemnification obligations to our officers and directors for certain events or occurrences, subject to certain limits, while they are serving at
our request in their respective capacities. There have been no claims to date and we have a director and officer insurance policy that enables us to recover a portion of any amounts paid for future potential claims.

NOTE 7. STOCK-BASED COMPENSATION

Stock Option Activities

For the three months ended March 31, 2009, stock option activity under
our plans is as follows:



|                               |  |                          |   |  |                 |   |  |                              |      
|------------------------------ |  | ------------------------ | - |  | --------------- | - |  | ---------------------------- | -----
|                               |  | SharesAvailablefor Grant |   |  | Number ofShares |   |  | WeightedAverageExercisePrice
|Balances, at December 31, 2008 |  | 1,697,112                |   |  | 3,178,837       |   |  | $                            | 5.83 
|Additional shares reserved     |  | 1,000,000                |   |  |                 |   |  |                              |      
|Options granted                |  | (935,000                 | ) |  | 935,000         |   |  | $                            | 10.23
|Options exercised              |  |                         |   |  | (56,421         | ) |  | $                            | 0.88 
|Options cancelled              |  | 28,913                   |   |  | (28,913         | ) |  | $                            | 9.23 
|                               |  |                          |   |  |                 |   |  |                              |      
|Balances, at March 31, 2009    |  | 1,791,025                |   |  | 4,028,503       |   |  | $                            | 6.90 
|                               |  |                          |   |  |                 |   |  |                              |      



13



---

##### Table of Contents

Stock-Based Compensation for Employees

The following table summarizes the stock-based compensation expense for stock options and our employee stock purchase plan that we recorded in the
condensed statements of operations in accordance with SFAS No.123(R) for the three months ended March 31, 2009 and 2008, respectively (in thousands).



|                                  |  |                              |       |      |   |    
|--------------------------------- |  | ---------------------------- | ----- | ---- | - | ---
|                                  |  | Three Months Ended March 31,
|                                  |  | 2009                         |       | 2008
|Research and development          |  | $                            | 476   |      | $ | 306
|Sales, general and administrative |  |                              | 775   |      |   | 437
|                                  |  |                              |       |      |   |    
|                                  |  | $                            | 1,251 |      | $ | 743
|                                  |  |                              |       |      |   |    

We used the following assumptions to estimate the fair value of options granted under our stock
option plans for the three months ended March 31, 2009 and 2008, respectively:



|                         |  |                              |   |  |      |  
|------------------------ |  | ---------------------------- | - |  | ---- | -
|                         |  | Three Months Ended March 31, |  
|                         |  | 2009                         |   |  | 2008 |  
|Risk-free interest rate  |  | 1.6%-1.8                     | % |  | 2.7  | %
|Expected volatility      |  | 62                           | % |  | 63   | %
|Expected term (in years) |  | 5.0                          |   |  | 5.5  |  
|Expected dividend yield  |  |                             |   |  |     |  

We used the following assumptions to estimate the fair value of shares purchased under our
employee stock purchase plan for the three months ended March 31, 2009 and 2008, respectively:



|                         |  |                              |   |  |      |  
|------------------------ |  | ---------------------------- | - |  | ---- | -
|                         |  | Three Months Ended March 31, |  
|                         |  | 2009                         |   |  | 2008 |  
|Risk-free interest rate  |  | 0.4                          | % |  | 2.9  | %
|Expected volatility      |  | 76                           | % |  | 81   | %
|Expected term (in years) |  | 0.5                          |   |  | 0.6  |  
|Expected dividend yield  |  |                             |   |  |     |  

Risk-Free Interest Rate:The risk-free interest rate assumption was based on U.S. Treasury
instruments with a term that is consistent with the expected term of our stock options.

Expected Volatility:The expected stock
price volatility for our common stock was determined by examining the historical volatilities for industry peers and using an average of the historical volatilities of our industry peers as we did not have any significant trading history for our
common stock. Industry peers consist of several public companies in the biopharmaceutical industry similar to us in size, stage of life-cycle and financial leverage.

Expected Term:The expected term of stock options represents the weighted average period the stock options are expected to remain outstanding. It was calculated based on the historical experience that we have
had with stock option grants as well as the expected term of industry peers, as we did not have sufficient historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for
the full term of our stock options. We will continue to analyze the historical stock price volatility and expected term assumptions as more historical data for our common stock becomes available.



14



---

##### Table of Contents

Expected Dividend Yield:The expected dividend yield of 0% is based on our history and expectation
of dividend payouts. We have not paid and do not anticipate paying any dividends in the near future, other than a certain cumulative dividend on preferred stock pursuant to the terms of our certificate of incorporation, which was paid in connection
with our initial public offering, or IPO.

Forfeitures:As stock-based compensation expense recognized in the condensed consolidated
statement of operations for the three months ended March 31, 2009 and 2008 is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. SFAS No. 123(R) requires forfeitures to be estimated at the time of
grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Forfeitures were estimated based on our historical experience.

As of March 31, 2009, there were unrecognized compensation costs of approximately $10.1 million related to non-vested stock option awards granted after January 1, 2006 that will be recognized on a
straight-line basis over the weighted average remaining period of 2.8 years.

Stock-Based Compensation for Non-Employees

Stock-based compensation expense related to stock options granted to non-employees is recognized as the stock options are earned.
Management believes that the fair value of the stock options is more reliably measurable than the fair value of the service received. The fair value of stock options granted to non-employees is calculated at each grant date and remeasured at each
reporting date. The stock-based compensation expense will fluctuate as the price of our common stock fluctuates. We recorded stock-based compensation expense for non-employees of $18,000, $94,000 and $0.8 million for the three months ended
March 31, 2009 and 2008 and for the cumulative period from July 3, 2003 (date of inception) through March 31, 2009, respectively.



15



---

##### Table of Contents

|ITEM 2. | MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
|------- | -------------------------------------------------------------------------------------

This quarterly report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the safe harbor created by those sections. Forward-looking statements are based on our managements beliefs
and assumptions and on information currently available to them. In some cases you can identify forward-looking statements by words such as may, will, should, could, would,
expects, plans, anticipates, believes, estimates, projects, predicts, potential and similar expressions intended to identify forward-looking statements.
Examples of these statements include, but are not limited to, statements regarding: the implications of interim or final results of our clinical trials, the progress of our research programs, including clinical testing, the extent to which our
issued and pending patents may protect our products and technology, our ability to identify new product candidates, the potential of such product candidates to lead to the development of commercial products, our anticipated timing for initiation or
completion of our clinical trials for any of our product candidates, our future operating expenses, our future losses, our future expenditures for research and development, and the sufficiency of our cash resources. Our actual results could differ
materially from those anticipated in these forward-looking statements for many reasons, including the risks faced by us and described in Part II, Item 1A of this quarterly report on Form 10-Q and our other filings with the SEC. You should not
place undue reliance on these forward-looking statements, which apply only as of the date of this quarterly report on Form 10-Q. You should read this quarterly report on Form 10-Q completely and with the understanding that our actual future results
may be materially different from those we expect. Except as required by law, we assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise.

The following discussion and analysis should be read in conjunction with the unaudited financial statements and notes thereto included in Part I,
Item 1 of this quarterly report on Form 10-Q and with the audited consolidated financial statements and related notes thereto included as part of our Annual Report on Form 10-K for the year ended December 31, 2008, as amended.

Overview

We use our proprietary
inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. We have several proprietary product
candidates in clinical development that address large market opportunities, including our two most advanced product candidates, Unit Dose Budesonide, or UDB, for the potential treatment of asthma in children and MAP0004 for the potential treatment
of migraine. UDB is our proprietary nebulized version of budesonide intended to treat asthma in children from 12 months to eight years of age. UDB is designed to be administered more quickly and to provide efficacy at lower doses than conventional
nebulized budesonide, which is the current leading nebulized treatment for asthma in children. MAP0004 is our proprietary orally inhaled version of dihydroergotamine intended to treat migraine. MAP0004 is designed to provide faster onset and longer
lasting pain relief than triptans, the class of drugs most often prescribed for treating migraine.

In December 2008, we entered into a
worldwide collaboration with AstraZeneca AB, or AstraZeneca, to develop and commercialize UDB, which became effective on February 2, 2009. We are jointly developing UDB with AstraZeneca in the United States and have the rights to co-promote UDB
in the United States.

We announced positive results from Phase 2 clinical studies of UDB and MAP0004 in early 2007. We initiated a Phase 3
clinical program for UDB in January 2008, and in February 2009, we announced top-line results from our first Phase 3 trial of UDB, indicating that the trial did not meet its co-primary endpoints in the two doses evaluated when compared to placebo.
We and our partner AstraZeneca are conducting further analyses of these data to determine appropriate next steps for the UDB program. For our MAP0004 migraine program we initiated a Phase 3 clinical program in July 2008 pursuant to a special
protocol assessment, or SPA, from the U.S. Food and Drug Administration, or FDA. In order to obtain regulatory approval for UDB and MAP0004, we will need to conduct additional Phase 3 and Phase 2 clinical trials. We hold worldwide commercialization
rights for MAP0004, and our goal is to market MAP0004 in the United States through our own focused sales force targeting neurologists and headache specialists. We may establish partnerships with pharmaceutical companies to market and sell to primary
care physicians and outside of the United States.

Our product portfolio also
includes two earlier stage product candidates, both of which highlight the broad applicability of our technologies to a diverse range of potential future products. MAP0005 is our proprietary combination of an inhaled corticosteroid and a long-acting
beta-agonist for the potential treatment of asthma and chronic obstructive pulmonary disease and MAP0001 is our proprietary form of insulin for the potential treatment of Type 1 and Type 2 diabetes via pulmonary delivery using our proprietary
Tempo® inhaler. While we do not plan to make further significant direct investment in these two product candidates, we plan to evaluate other potential product candidates which may utilize
these technologies, as well as partnership opportunities for further development and commercialization of these two product candidates.

We
are a development stage company and have not generated any product revenues. Since our inception, we have incurred losses and have an accumulated deficit of $185.8 million as of March 31, 2009. We have financed our operations through equity
financing, debt financing, the issuance of convertible notes and collaboration payments. Prior to our IPO, in October 2007, we received net proceeds of $106.7 million from the issuance of convertible notes and convertible preferred stock. With the
completion of our IPO we received net proceeds of $62.1 million after deducting expenses and underwriters discounts and commissions. In 2006, we entered into a loan facility agreement and borrowed $10.0 million to finance working capital,
or the 2006 Working Capital Loan, and a $1.0 million loan facility to finance equipment purchases. In May 2008, we entered into an agreement to borrow $20.0 million, or the 2008 Working Capital Loan, in order to repay the 2006 Working Capital Loan
and to support general corporate purposes. We received $40.0 million as a nonrefundable upfront payment from AstraZeneca in February 2009.



16



---

##### Table of Contents

We expect to continue to incur net losses for the next several years as we continue to develop our
current product candidates, develop, acquire or in-license additional products or product candidates, expand clinical trials for our product candidates currently in clinical development, expand our research and development activities, seek
regulatory approvals and engage in commercialization preparation activities in anticipation of potential FDA approval of our product candidates. We will need to expand our commercial organization to launch any products. Significant capital is
required to launch a product, and many expenses are incurred before revenues are received. We are unable to predict the extent of any future losses or when we will become profitable, if at all.

AstraZeneca License Agreement

In December 2008, we
entered into a license agreement with AstraZeneca, which became effective in February 2009. Pursuant to the terms of the agreement, we licensed to AstraZeneca global rights to develop and commercialize our proprietary nebulized formulation of UDB,
our next generation UDB therapy and certain combination nebulization therapies for the potential treatment of asthma in children.

We are
jointly developing UDB in the United States with AstraZeneca, and we are responsible for executing the development plan. AstraZeneca reimburses us for the costs of future UDB development activities beginning on the effective date and has the right
to develop follow-on products using different nebulizers and certain products combining nebulized budesonide with other drugs. AstraZeneca has rights to commercialize UDB in the United States and to develop and commercialize UDB outside of the
United States.

AstraZeneca will pay for up to a 60-person sales force for the company to co-promote UDB with AstraZeneca in the United
States after product launch. AstraZeneca will provide funding for this sales force for up to five years after product launch. In February 2009, under the terms of this agreement, AstraZeneca paid us a nonrefundable upfront cash payment of $40
million. The agreement also provided for a $35 million milestone payment payable upon the successful achievement of co-primary endpoints and safety results in our initial Phase 3 clinical trial. In addition, we are eligible to receive up to $240
million in other development and regulatory milestones. The agreement also provides for additional progressively demanding sales performance-related milestone payments of up to $585 million in the event the product is a considerable commercial
success.

We are also eligible to receive significant and escalating double-digit royalty payments on worldwide sales, as well as
reimbursement for all royalties payable to Elan Pharma International Limited or Elan under our license agreement with Elan. These payments will begin following the date of the first commercial sale of UDB or any other licensed product. We are also
eligible to receive reimbursement for a portion of certain milestone payments payable to Elan. Under the terms of the agreement, both companies agree, under certain circumstances, for a period until three years after the first commercial sale of a
licensed product in the United States, not to commercialize or assist any third party in commercializing certain competing products. We also have the right to terminate the agreement in relation to licensed products developed for administration
solely using jet nebulizers if AstraZeneca commercializes certain competing products for use in jet nebulizers.

Either party may terminate
the agreement upon a material, uncured default of the other party. AstraZeneca may terminate the agreement, with or without cause, at any time upon 90 days prior written notice. If AstraZeneca terminates the agreement under certain
circumstances, AstraZeneca will be obligated to reimburse our remaining development costs under the development plan. Our failure to meet co-primary endpoints in our initial Phase 3 clinical trial, gives AstraZeneca the right to terminate the
agreement, or continue with the collaboration without paying the $35 million milestone. AstraZeneca has 60 days from deemed receipt of the complete data package from our initial Phase 3 clinical trial to decide whether to terminate the agreement. If
AstraZeneca proceeds with the collaboration, AstraZeneca will be responsible for reimbursing the remaining development costs we incur under the development plan.

On February 23, 2009, we announced top-line results of our initial Phase 3 clinical trial of UDB for the potential treatment of children with asthma. We announced that the clinical trial did not meet its
co-primary endpoints, asthma control as assessed by changes from baseline in nighttime and daytime composite symptom scores, in either of the doses evaluated when compared with placebo.

Critical Accounting Policies and Significant Judgments and Estimates

With the exception of the
Revenue Recognition policy discussed below, there have been no changes in critical accounting policies during the three months ended March 31, 2009, as compared to the critical accounting policies described in
Item 7Managements Discussion and Analysis of Financial Condition and Results of OperationsCritical Accounting Policies and Significant Judgments and Estimatesin our Annual Report on Form 10-K for the fiscal
year ended December 31, 2008, as amended.



17



---

##### Table of Contents

Revenue Recognition

We recognize revenue in accordance with SEC Staff Accounting Bulletin, or SAB, No. 104, Revenue Recognition. SAB No. 104 requires that certain criteria must be met before revenue can be
recognized: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; the fee is fixed or determinable; and collectability is reasonably assured. Determination of whether persuasive evidence of an
arrangement exists and whether delivery has occurred or services have been rendered are based on managements judgments regarding the fixed nature of the fee charged for research performed and milestones met, and the collectability of those
fees. Should changes in conditions cause management to determine these criteria are not met for certain future transactions, revenue recognized for any reporting period could be adversely affected.

Collaboration revenue, which is earned under agreements with third parties for research and development activities, may include nonrefundable license
fees, cost reimbursements and contingent milestones and royalties. Our revenue arrangements with multiple elements are evaluated under Emerging Issues Task Force, or EITF Issue No. 00-21, Revenue Arrangements with Multiple Deliverables,
and are divided into separate units of accounting if certain criteria are met, including whether the delivered element has stand-alone value and whether there is objective and reliable evidence of the fair value of the undelivered items. The
consideration we receive is allocated among the separate units based on their respective fair values, and the applicable revenue recognition criteria are applied to each of the separate units.

Upfront payments received upon execution of collaborative agreements are recorded as deferred revenue and recognized as collaboration revenue over the
research and development period pursuant to the agreement. Such period generally represents the research and development period set forth in the agreement between our third party collaborator and us. Research and development period is estimated at
the inception of the arrangement and is periodically reevaluated. Reevaluation of the research and development period may shorten or lengthen the period during which the deferred revenue is recognized. We evaluate the appropriate period based on
research progress attained and reevaluate the period when significant changes occur.

Cost reimbursements are based upon negotiated rates
for our full time employee equivalents, or FTE, and actual out-of-pocket costs. They are recognized as collaboration revenue as the related research and development services are performed. The cost reimbursements are generally based on qualified
expenses as defined in the collaborative agreement. FTE rates are intended to approximate our anticipated cost.

We recognize milestone
payments as revenue upon achievement of the milestone provided the milestone payment is nonrefundable, substantive effort and risk is involved in achieving the milestone and the amount of the milestone is reasonable in relation to the effort
expended or risk associated with the achievement of the milestone. If these conditions are not met, we defer the milestone payment and recognize it as revenue over the estimated period of performance under the contract as we complete our performance
obligations.

Financial Overview

Collaboration
Revenue

We recognize revenues from collaborative research and development activities. Collaboration revenue, which is earned under
agreements with third parties for research and development activities, may include nonrefundable upfront payments, cost reimbursements and milestone payments. Total collaboration revenue recognized under the AstraZeneca arrangement was $7.5 million,
$0 and $7.5 million for the three months ended March 31, 2009 and 2008 and for the cumulative period from July 3, 2003 (date of inception) to March 31, 2009, respectively.

We expect our collaboration revenue to fluctuate in future periods based on the progress of our existing collaboration.

Research and Development Expenses

Research
and development expenses consist of: (i) expenses incurred under agreements with contract research organizations and investigative sites, which conduct our clinical trials and a substantial portion of our pre-clinical studies;
(ii) milestone payments paid to our collaborative partners who work on our processing and supply of clinical trial material; (iii) the cost of manufacturing and supplying clinical trial materials; (iv) payments to contract service
organizations, as well as consultants; (v) employee-related expenses, which include salaries and benefits; (vi) facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent and maintenance of
facilities and equipment, depreciation of leasehold improvements and equipment and laboratory and other supplies; and (vii) stock-based compensation expense. All research and development expenses are expensed as incurred.

Conducting a significant amount of research and development is central to our business model. Through March 31, 2009, we incurred approximately
$145.8 million in research and development expenses since our inception in 2003. Product candidates in later-stage clinical development generally have higher development costs than those in earlier stages of development, primarily due to the



18



---

##### Table of Contents

significantly increased size and duration of clinical trials. We plan to increase our research and development expenses for the foreseeable future in order
to complete development of our two most advanced product candidates, UDB and MAP0004, and earlier-stage research and development projects. Pursuant to our agreement with AstraZeneca, effective February 2, 2009, AstraZeneca began reimbursing us
for the development costs related to the UDB program.

The following table summarizes the percentages of our research and development
expenses related to our two most advanced product candidates and other earlier stage projects. The percentages summarized in the following table reflect costs directly attributable to each development candidate, which are tracked on a project basis.
A portion of our internal costs, including indirect costs relating to our product candidates, is not tracked on a project basis and is allocated based on management estimates.



|                                      |  |                              |   |  |                                                                |   |  |     |  
|------------------------------------- |  | ---------------------------- | - |  | -------------------------------------------------------------- | - |  | --- | -
|                                      |  | Three Months Ended March 31, |   |  | Period fromJuly 3, 2003(Date of Inception)throughMarch 31,2009 |  
|                                      |  | 2009                         |   |  | 2008                                                           |   |  |     |  
|Our most advanced product candidates: |  |                              |   |  |                                                                |   |  |     |  
|UDB                                   |  | 46                           | % |  | 49                                                             | % |  | 45  | %
|MAP0004                               |  | 49                           | % |  | 43                                                             | % |  | 47  | %
|Other projects                        |  | 5                            | % |  | 8                                                              | % |  | 8   | %
|                                      |  |                              |   |  |                                                                |   |  |     |  
|Total                                 |  | 100                          | % |  | 100                                                            | % |  | 100 | %
|                                      |  |                              |   |  |                                                                |   |  |     |  

The process of conducting pre-clinical studies and clinical trials necessary to obtain FDA
approval is costly and time consuming. The probability of success for each product candidate and clinical trial may be affected by a variety of factors, including, among other things, the quality of the product candidates early clinical data,
investment in the program, competition, manufacturing capabilities and commercial viability. As a result of the uncertainties discussed above, uncertainty associated with clinical trial enrollment and risks inherent in the development process, we
are unable to determine the duration and completion costs of current or future clinical stages of our product candidates or when, or to what extent, we will generate revenues from the commercialization and sale of any of our product candidates.
Development timelines, probability of success and development costs vary widely. We are currently focused on developing our two most advanced product candidates. However, we may need to raise substantial additional capital in the future in order to
complete the development and potential commercialization of UDB and MAP0004 and other product candidates.

Sales, General and Administrative Expenses

Sales, general and administrative expenses consist primarily of compensation for executive, finance, marketing, legal and
administrative personnel, including share-based compensation. Other sales, general and administrative expenses include facility costs not otherwise included in research and development expenses, legal and accounting services, other professional
services, the cost of market research activities and consulting fees. Through March 31, 2009, we incurred approximately $36.9 million in sales, general and administrative expenses since our inception in 2003. We expect these expenses to
increase as our business continues to grow.

Results of Operations

Comparison of Three Months Ended March 31, 2009 and 2008

Collaboration Revenue

The collaboration revenue includes amortization of the nonrefundable upfront payment and reimbursement of qualified development expenses.
The collaboration revenue as compared to the prior year is as follows (in thousands):



|                      |  |                              |       |      |   |  
|--------------------- |  | ---------------------------- | ----- | ---- | - | -
|                      |  | Three Months Ended March 31,
|                      |  | 2009                         |       | 2008
|Collaboration revenue |  | $                            | 7,484 |      | $ | 

The increase in collaboration revenue was due to our license agreement with AstraZeneca, which
became effective on February 2, 2009.



19



---

##### Table of Contents

Research and Development Expenses

Research and development expenses and percentage changes as compared to the prior year are as follows (dollar amounts are presented in thousands):



|                                  |  |                              |        |                     |   |                       |  |   |       |  |    |  
|--------------------------------- |  | ---------------------------- | ------ | ------------------- | - | --------------------- |  | - | ----- |  | -- | -
|                                  |  | Three Months Ended March 31, |        | Increase/(Decrease) |   | % Increase/(Decrease) | 
|                                  |  | 2009                         |        | 2008                |   |                      
|Research and development expenses |  | $                            | 14,075 |                     | $ | 11,815                |  | $ | 2,260 |  | 19 | %

The increase in research and development expenses was driven primarily by an increase of $1.8
million in clinical expenses to support Phase 3 clinical programs for our two lead product candidates, UDB and MAP0004, and an increase of $0.4 million in personnel related expenses to support these clinical programs.

Sales, General and Administrative Expenses

Sales, general and administrative expenses and percentage changes as compared to the prior year are as follows (dollar amounts are presented in thousands):



|                                           |  |                              |       |                     |   |       |                       |   |      |   |  |     |   
|------------------------------------------ |  | ---------------------------- | ----- | ------------------- | - | ----- | --------------------- | - | ---- | - |  | --- | --
|                                           |  | Three Months Ended March 31, |       | Increase/(Decrease) |   |       | % Increase/(Decrease) |  
|                                           |  | 2009                         |       | 2008                |   |      
|Sales, general and administrative expenses |  | $                            | 2,808 |                     | $ | 3,140 |                       | $ | (332 | ) |  | (11 | )%

The decrease in sales, general and administrative expenses was related primarily to a decrease of
$0.4 million in professional fees and a decrease of $0.2 million in other miscellaneous fees, partially offset by an increase of $0.3 million in stock-based compensation.

Interest Income

Interest income and percentage changes as compared to the prior year are as follows
(dollar amounts are presented in thousands):



|                |  |                              |    |                     |   |     |                       |   |      |   |  |     |   
|--------------- |  | ---------------------------- | -- | ------------------- | - | --- | --------------------- | - | ---- | - |  | --- | --
|                |  | Three Months Ended March 31, |    | Increase/(Decrease) |   |     | % Increase/(Decrease) |  
|                |  | 2009                         |    | 2008                |   |    
|Interest income |  | $                            | 85 |                     | $ | 853 |                       | $ | (768 | ) |  | (90 | )%

The decrease in interest income was due primarily to decreased cash, cash equivalents and
short-term investment balances at March 31, 2009 as compared to that at March 31, 2008, as well as a decrease in market interest rates. We expect our interest income to fluctuate in the future due to changes in average investment balances
and market interest rates.

Interest Expense

Interest expense and percentage changes as compared to the prior year are as follows (dollar amounts are presented in thousands):



|                 |  |                              |     |                     |   |                       |  |   |     |  |    |  
|---------------- |  | ---------------------------- | --- | ------------------- | - | --------------------- |  | - | --- |  | -- | -
|                 |  | Three Months Ended March 31, |     | Increase/(Decrease) |   | % Increase/(Decrease) | 
|                 |  | 2009                         |     | 2008                |   |                      
|Interest expense |  | $                            | 602 |                     | $ | 310                   |  | $ | 292 |  | 94 | %

The increase in interest expense was due primarily to higher debt balances related to the 2008
Working Capital Loan. We expect our interest expense to fluctuate in the future with average debt balances.



20



---

##### Table of Contents

Other Income (Expense), Net.

Other income (expense), net and percentage changes as compared to the prior year are as follows (dollar amounts are presented in thousands):



|                            |  |                              |    |                     |      |   |                       |  |   |      |   |  |      |   
|--------------------------- |  | ---------------------------- | -- | ------------------- | ---- | - | --------------------- |  | - | ---- | - |  | ---- | --
|                            |  | Three Months Ended March 31, |    | Increase/(Decrease) |      |   | % Increase/(Decrease) | 
|                            |  | 2009                         |    |                     | 2008 |   |                      
|Other income (expense), net |  | $                            | (4 | )                   |      | $ | 112                   |  | $ | (116 | ) |  | (104 | )%

In the first quarter of 2008, we incurred gains of $94,000 from the sale of investments. We did
not incur any such transaction in the first quarter of 2009 and, as a result, there was a decrease in other income (expense), net.

Liquidity and
Capital Resources

Liquidity

We have incurred losses since our inception in July 2003 and as of March 31, 2009 we had an accumulated deficit of $185.8 million. We will continue to be in a loss position until sufficient revenue can be generated to offset our
expenses, and we anticipate that we will continue to incur net losses for the next several years. We expect that our research and development and sales, general and administrative expenses may continue to increase and, as a result, we will need to
generate significant net product sales, royalty and other revenues to achieve profitability.

We have financed our operations through
equity financing, debt financing, the issuance of convertible notes and collaboration payments. Prior to our IPO, in October 2007, we received net proceeds of $106.7 million from the issuance of convertible notes and convertible preferred stock.
With the completion of our IPO we received net proceeds of $62.1 million after deducting expenses and underwriters discounts and commissions. In 2006, we entered into the 2006 Working Capital Loan, and a $1.0 million loan facility to
finance equipment purchases. In May 2008, we entered into the 2008 Working Capital Loan, in order to repay the 2006 Working Capital Loan and to support general corporate purposes. We received $40.0 million as a nonrefundable upfront payment from
AstraZeneca in February 2009.

As of March 31, 2009, we had approximately $67.7 million in cash and cash equivalents. Our cash
and cash equivalents are primarily held in money market funds. Cash in excess of immediate requirements is invested in accordance with our investment policy with a view toward capital preservation and liquidity.

Cash Flow

The following table shows a summary
of our cash flows for the periods indicated (in thousands):



|                            |  |                              |        |   |      |   |         |  
|--------------------------- |  | ---------------------------- | ------ | - | ---- | - | ------- | -
|                            |  | Three Months Ended March 31, |       
|                            |  | 2009                         |        |   | 2008 |  
|Cash provided by (used in): |  |                              |        |   |      |   |         |  
|Operating activities        |  | $                            | 24,245 |   |      | $ | (12,942 | )
|Investing activities        |  |                              | 12,638 |   |      |   | (3,099  | )
|Financing activities        |  |                              | (1,105 | ) |      |   | (728    | )

Net cash provided by (used in) operating activities. We received $24.2 million of cash
from operating activities for the three months ended March 31, 2009 compared to the usage of cash of $12.9 million for the corresponding period in 2008. The cash provided by operating activities for the three months ended March 31, 2009
was due primarily to a $40.0 million nonrefundable upfront payment we received from AstraZeneca, partially offset by a net loss of $9.9 million for the three months ended March 31, 2009 and by an increase in accounts receivable of $4.7 million
from AstraZeneca. The usage of cash of $12.9 million for the three months ended March 31, 2008 was due primarily to a net loss of $14.3 million, partially offset by stock-based compensation of $0.8 million and an increase in accrued liabilities
of $0.7 million.

Net cash provided by (used in) investing activities. We received $12.6 million of cash from investing
activities for the three months ended March 31, 2009 compared to the usage of cash of $3.1 million for the corresponding period in 2008. The cash provided by investing activities was due primarily to sales and maturities of our short-term
investments of $12.7 million. There were no purchases of investments for the three months ended March 31, 2009.

Net cash used in
financing activities. We used $1.1 million of cash for financing activities for the three months ended March 31, 2009 compared to $0.7 million for the corresponding period in 2008. The increase was due primarily to higher repayments
made on outstanding debt in the three months ended March 31, 2009 compared to the same period in 2008.

Agreement with Nektar

Under the June 2004 agreement, as amended, with Nektar Therapeutics UK Limited, or Nektar Agreement, we were granted a
worldwide, exclusive license, with a right to sublicense, under Nektar patents and know-how, to develop and commercialize any formulation of a form of dihydroergotamine for administration by inhalation using a device. We also agreed to pay royalties
at specified rates based on net sales. As of March 31, 2009, we are required to make future nonrefundable milestone payments of up to $5.0 million related to products currently being developed under this agreement, when and if certain
regulatory and commercial milestones are met. We paid $0, $0 and $2.6 million related to milestones for the three months ended March 31, 2009 and 2008 and for the cumulative period from July 3, 2003 (date of inception) to March 31,
2009, respectively. Either party may terminate the Nektar Agreement upon a material, uncured default of the other party. We may terminate the agreement, with or without cause, at any time upon six months prior written notice.



21



---

##### Table of Contents

Agreement with Elan

Under the April 2004 agreement, as amended, with Elan Pharma International Limited, or Elan Agreement, Elan granted to us a worldwide, exclusive, sub-licensable license under Elans intellectual property
rights to use, market, distribute, sell, have sold , offer for sale, import and export certain ingredients for our UDB product candidate. We also agreed to pay royalties at specified rates based on net sales. As of March 31, 2009, we are
required to make future nonrefundable milestone payments of up to $16.5 million related to products currently being developed under this agreement, when and if certain regulatory and commercial milestones are met with respect to our UDB product
candidate. We paid $0, $0.8 million and $4.0 million related to milestones for the three months ended March 31, 2009 and 2008 and for the cumulative period from July 3, 2003 (date of inception) to March 31, 2009, respectively. Either
party may terminate the Elan Agreement upon a material, uncured default of the other party. We may terminate the agreement, with or without cause, at any time upon 90 days prior written notice. We also entered into a services agreement with
Elan Drug Delivery International in February 2005. In connection with the execution of the license agreement with AstraZeneca, we amended the Elan agreements, pursuant to which AstraZeneca will have certain rights to exercise and enforce certain of
our rights with Elan prior to the expiration or termination of the AstraZeneca Agreement. The amendments did not impact our unaudited condensed consolidated financial statements.

Operating Capital and Capital Expenditure Requirements

Our future capital requirements will
depend on many forward looking factors and are not limited to the following:



| |  |  | the initiation, progress, timing and completion of clinical trials for our product candidates and potential product candidates;
| | - |  | -------------------------------------------------------------------------------------------------------------------------------



| |  |  | the status of our collaboration with AstraZeneca;
| | - |  | -------------------------------------------------



| |  |  | our ability to achieve milestones under our license agreements including our agreement with AstraZeneca;
| | - |  | --------------------------------------------------------------------------------------------------------



| |  |  | the outcome, the timing and the cost of regulatory approvals;
| | - |  | -------------------------------------------------------------



| |  |  | delays that may be caused by changing regulatory requirements;
| | - |  | --------------------------------------------------------------



| |  |  | the number of product candidates that we pursue;
| | - |  | ------------------------------------------------



| |  |  | the costs involved in filing and prosecuting patent applications and enforcing and defending patent claims;
| | - |  | -----------------------------------------------------------------------------------------------------------



| |  |  | the timing and terms of future in-licensing and out-licensing transactions;
| | - |  | ---------------------------------------------------------------------------



| |  |  | the cost and timing of establishing sales, marketing and distribution capabilities;
| | - |  | -----------------------------------------------------------------------------------



| |  |  | the cost of procuring clinical and commercial supplies of our product candidates;
| | - |  | ---------------------------------------------------------------------------------



| |  |  | the extent to which we acquire or invest in businesses, products or technologies; and
| | - |  | -------------------------------------------------------------------------------------



| |  |  | the possible costs of litigation.
| | - |  | ---------------------------------

We believe that our existing cash, including a $40.0 million nonrefundable upfront cash payment we received in February 2009 in connection with our license agreement with AstraZeneca, cash equivalents, short-term investments and
reimbursements from AstraZeneca for certain future costs, will be sufficient to fund our projected operating requirements for at least 12 months. In addition, we may need to raise substantial additional capital in the future in order to complete the
development and commercialization of MAP0004 and to fund the development and commercialization of our future product candidates. Until we can generate a sufficient amount of product revenue, if ever, we expect to finance future cash needs through
public or private equity offerings, debt financings or corporate collaboration and licensing arrangements. Such funding, if needed, may not be available on favorable terms, if at all. In the event we are unable to obtain additional capital, we may
delay or reduce the scope of our current research and development programs and other expenses.

As widely reported, financial markets in
the United States, Europe and Asia have been experiencing extreme disruption in recent months, including, among other things, extreme volatility in security prices, severely diminished liquidity and credit availability, rating downgrades of certain
investments and declining valuations of others. Governments have taken unprecedented actions intended to address extreme market conditions that include severely restricted credit and declines in real estate values. Concern about the stability of the
markets generally and the strength of counterparties specifically has led many lenders and institutional investors to reduce, and in some cases, cease to provide funding to borrowers. Continued turbulence in the U.S. and international markets and
economies may limit our ability to access the capital markets to meet our funding requirements. If adequate funds are not available,



22



---

##### Table of Contents

we may be required to delay, reduce the scope of or eliminate one or more of our research or development programs or our commercialization efforts. To the
extent that we raise additional funds by issuing equity securities, our stockholders may experience additional significant dilution, and debt financing, if available, may involve restrictive covenants. To the extent that we raise additional funds
through collaboration and licensing arrangements, it may be necessary to relinquish some rights to our technologies or our product candidates or grant licenses on terms that may not be favorable to us. We may seek to access the public or private
capital markets whenever conditions are favorable, even if we do not have an immediate need for additional capital at that time.

Recent Accounting
Pronouncements

In April 2009, the FASB issued FASB Staff Position, or FSP, FAS 157-4, Determining Fair Value When the Volume and
Level of Activity for the Asset or Liability Have Significantly Decreased and Identifying Transactions That Are Not Orderly. FSP FAS 157-4 provides guidelines for making fair value measurements more consistent with the principles presented in
FASB Statement No. 157, Fair Value Measurements. FSP FAS 157-4 relates to determining fair values when there is no active market or where the price inputs being used represent distressed sales. It reaffirms what Statement 157 states is
the objective of fair value measurementto reflect how much an asset would be sold for in an orderly transaction (as opposed to a distressed or forced transaction) at the date of the financial statements under current market conditions.
Specifically, it reaffirms the need to use judgment to ascertain if a formerly active market has become inactive and in determining fair values when markets have become inactive. FSP FAS 157-4 is effective for interim and annual periods ending after
June 15, 2009. As a result, it is effective for us in the second quarter of fiscal 2009. We do not believe that the adoption of FSP FAS 157-4 will have a material impact on our financial statements.

In April 2009, the FASB issued FSP FAS 107-1 and APB 28-1, Interim Disclosures about Fair Value of Financial Instruments. FSP FAS 107-1 and APB
28-1 enhance consistency in financial reporting by increasing the frequency of fair value disclosures. FSP FAS 107-1 and APB 28-1 relate to fair value disclosures for any financial instruments that are not currently reflected on the balance sheet of
companies at fair value. Prior to issuing this FSP, fair values for these assets and liabilities were only disclosed once a year. The FSP now requires these disclosures to be made on a quarterly basis, providing qualitative and quantitative
information about fair value estimates for all those financial instruments not measured on the balance sheet at fair value. FSP FAS 107-1 and APB 28-1 are effective for interim and annual periods ending after June 15, 2009. As a result, they
are effective for us in the second quarter of fiscal 2009. We do not believe that the adoption of FSP FAS 107-1 and APB 28-1 will have a material impact on our financial statements.

Off-Balance Sheet Arrangements

Since our inception, we have not engaged in any off-balance sheet
arrangements, including the use of structured finance, special purpose entities or variable interest entities.



|ITEM 3. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
|------- | ----------------------------------------------------------

Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates. We do not have any foreign currency or other derivative financial instruments.

We believe that there have been no significant changes in our market risk exposures for the three months ended March 31, 2009.



|ITEM 4. | CONTROLS AND PROCEDURES
|------- | -----------------------

Evaluation of
Disclosure Controls and Procedures: As required by paragraph (b) of Exchange Act Rules 13a-15 or 15d-15, our management, including our Chief Executive Officer and Chief Financial Officer, conducted an evaluation as of the end of
the period covered by this report, of the effectiveness of our disclosure controls and procedures as defined in Exchange Act Rule 13a-15(e) and 15d-15(e). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer
concluded that our disclosure controls and procedures were effective as of the end of March 31, 2009, the period covered by this report.

Changes in Internal Control Over Financial Reporting: There were no significant changes in our internal control over financial reporting during our most recently completed fiscal quarter that has materially affected, or is reasonably
likely to materially affect, our internal control over financial reporting.



23



---

##### Table of Contents

PART II. OTHER INFORMATION



|ITEM 1. | LEGAL PROCEEDINGS
|------- | -----------------

We are not a party to any
material legal proceeding.



|ITEM 1A. | RISK FACTORS
|-------- | ------------

Certain factors may have a
material adverse effect on our business, financial condition and results of operations, and you should carefully consider them. Accordingly, in evaluating our business, we encourage you to consider the following discussion of risk factors, in its
entirety, in addition to other information contained in this report as well as our other public filings with the Securities and Exchange Commission.

Risks Relating to Our Financial Position and Need for Additional Capital

We have a history of net losses.
Currently, we have no products approved for commercial sale, and to date we have not generated any product revenue. As a result, we expect to continue to incur substantial and increasing net losses for the foreseeable future, and we may never
achieve or maintain profitability.

We are not profitable and do not expect to be profitable in the foreseeable future. We have
incurred significant net losses and negative cash flow in each year since our inception, including net losses of approximately $25.8 million, $40.1 million and $72.9 million, for the years ended December 31, 2006, 2007 and 2008, respectively.
As of March 31, 2009, we had a deficit accumulated during development stage of approximately $185.8 million. We have devoted most of our financial resources to research and development, including our pre-clinical development activities and
clinical trials. We have not completed development of any product candidate and have therefore not generated any product revenues. In that regard, we expect our expenses to increase as we continue with our Phase 3 clinical programs for our two
most advanced product candidates and conduct other clinical trials. In addition, if we are required by the U.S. Food and Drug Administration, or the FDA, to perform studies in addition to those we currently anticipate, our expenses will increase
beyond expectations and the timing of any potential product approval may be delayed. We also expect an increase in our expenses associated with our manufacturing work and with preparing for commercialization and we expect to continue to incur costs
to support operations as a public company. As a result, we may incur substantial and increasing net losses and negative cash flow for the foreseeable future. These losses and negative cash flows have had, and will continue to have, an adverse effect
on our stockholders equity and working capital.

Because of the numerous risks and uncertainties associated with pharmaceutical
product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve or maintain profitability. In addition, our expenses could increase beyond expectations if we are required
by the FDA to perform studies in addition to those that we currently anticipate. Currently, we have no products approved for commercial sale, and to date we have not generated any product revenue. We have financed our operations primarily through
the sale of equity securities, debt financings and collaboration payments. The size of our future net losses will depend, in part, on the rate of growth of our expenses and the rate of growth, if any, of our revenues. Additionally, pursuant to our
license agreement with AstraZeneca AB, or AstraZeneca, entered into in December 2008 and effective in February 2009, AstraZeneca agreed to fund our remaining development activities for Unit Dose Budesonide, or UDB, and to reimburse us for costs we
incur with respect to future UDB development activities conducted for the U.S. registration, subject to the terms and conditions of the license agreement. If the license agreement is terminated under certain conditions, AstraZeneca will not be
obligated to pay for such costs. Revenues from potential additional strategic partnerships are uncertain because we may not enter into any additional strategic partnerships. If we are unable to develop and commercialize one or more of our product
candidates or if sales revenue from any product candidate that receives marketing approval is insufficient, we will not achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability.

We have a limited operating history, and we expect a number of factors to cause our operating results to fluctuate on a quarterly and annual basis, which may make
it difficult to predict our future performance.

Our operations to date have been primarily limited to organizing and staffing our
company, developing our technology and undertaking pre-clinical studies and clinical trials of our product candidates. We have not yet obtained regulatory approvals for any of our product candidates. Consequently, any predictions you make about our
future success or viability may not be as accurate as they could be if we had a longer operating history. Specifically, our financial condition and operating results have varied significantly in the past and will continue to fluctuate from
quarter-to-quarter and year-to-year in the future due to a variety of factors, many of which are beyond our control. Factors relating to our business that may contribute to these fluctuations include the following factors, among others:



| |  |  | our ability to obtain additional funding to develop our product candidates;
| | - |  | ---------------------------------------------------------------------------



24



---

##### Table of Contents

| |  |  | the need to obtain regulatory approval of our two most advanced product candidates, UDB for asthma in children, and MAP0004 for migraine;
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------------



| |  |  | delays in the commencement, enrollment and completion of clinical testing, as well as the analysis and reporting of results from such clinical testing;
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | our ability to manage our supply chain for the study drug, other clinical materials and potentially approved products;
| | - |  | ----------------------------------------------------------------------------------------------------------------------



| |  |  | the success of clinical trials of our UDB and MAP0004 product candidates or future product candidates;
| | - |  | ------------------------------------------------------------------------------------------------------



| |  |  | the FDAs determination of the special protocol assessment, or SPA, we entered into for MAP0004;
| | - |  | ------------------------------------------------------------------------------------------------



| |  |  | any delays in regulatory review and approval of product candidates in clinical development;
| | - |  | -------------------------------------------------------------------------------------------



| |  |  | our ability to receive regulatory approval or commercialize our product candidates;
| | - |  | -----------------------------------------------------------------------------------



| |  |  | regulatory difficulties relating to products that have already received regulatory approval;
| | - |  | --------------------------------------------------------------------------------------------



| |  |  | our ability to rely on Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act, or FFDCA, to seek FDA marketing approval of our product candidates;
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | market acceptance of our product candidates for which we obtain regulatory approval;
| | - |  | ------------------------------------------------------------------------------------



| |  |  | our ability, and our partners ability, to establish an effective sales and marketing infrastructure;
| | - |  | -----------------------------------------------------------------------------------------------------



| |  |  | competition from existing products or new products that may emerge;
| | - |  | -------------------------------------------------------------------



| |  |  | the impact of competition, including generics, in the pediatric asthma market on our ability, and our partners ability, to commercialize UDB;
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | the impact of competition, including generics, in the migraine market on our ability to commercialize MAP0004;
| | - |  | --------------------------------------------------------------------------------------------------------------



| |  |  | guidelines and recommendations of therapies published by various organizations;
| | - |  | -------------------------------------------------------------------------------



| |  |  | the ability of patients to obtain coverage of or sufficient reimbursement for our products;
| | - |  | -------------------------------------------------------------------------------------------



| |  |  | the ability to receive regulatory approval or commercialize our products;
| | - |  | -------------------------------------------------------------------------



| |  |  | potential side effects of our future products that could delay or prevent commercialization or cause an approved drug to be taken off the market;
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | guidelines and recommendations of therapies published by various organizations;
| | - |  | -------------------------------------------------------------------------------



| |  |  | potential product liability claims;
| | - |  | -----------------------------------



| |  |  | potential liabilities associated with hazardous materials;
| | - |  | ----------------------------------------------------------



| |  |  | our ability to maintain adequate insurance policies;
| | - |  | ----------------------------------------------------



| |  |  | our dependency on third-party manufacturers to supply or manufacture our products;
| | - |  | ----------------------------------------------------------------------------------



| |  |  | our ability to establish or maintain collaborations, licensing or other arrangements, including our collaboration with AstraZeneca;
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------



| |  |  | our ability, our partners abilities, and third parties abilities to protect and assert intellectual property rights;
| | - |  | ----------------------------------------------------------------------------------------------------------------------



| |  |  | costs related to and outcomes of potential intellectual property litigation;
| | - |  | ----------------------------------------------------------------------------



| |  |  | compliance with obligations under intellectual property licenses with third parties;
| | - |  | ------------------------------------------------------------------------------------



| |  |  | our ability to adequately support future growth;
| | - |  | ------------------------------------------------



| |  |  | our ability to attract and retain key personnel to manage our business effectively; and
| | - |  | ---------------------------------------------------------------------------------------



| |  |  | the level of experience in running a public company of our senior management, many of whom are new to their current roles.
| | - |  | --------------------------------------------------------------------------------------------------------------------------

Due to the various factors mentioned above, and others, the results of any prior quarterly or annual periods should not be relied upon as indications of
our future operating performance.



25



---

##### Table of Contents

We will need substantial additional funding and if we are unable to raise capital when needed, we would be forced to
delay, reduce or eliminate our product development programs.

Developing biopharmaceutical products, including conducting pre-clinical
studies and clinical trials and establishing manufacturing capabilities, is expensive. We expect our research and development expenses to increase in connection with our ongoing activities, particularly as we proceed with our Phase 3 clinical
programs and conduct our other clinical trials of our two most advanced product candidates. In addition, our expenses could increase beyond expectations if the FDA requires that we perform additional studies to those that we currently anticipate, in
which case the timing of any potential product approval may be delayed. We believe that our existing cash, including a $40.0 million nonrefundable upfront cash payment we received in February 2009 in connection with our license agreement with
AstraZeneca, cash equivalents, short-term investments and reimbursements from AstraZeneca for certain future costs, will be sufficient to fund our projected operating requirements for at least 12 months. In addition, we may need to raise substantial
additional capital in the future in order to complete the development and commercialization of MAP0004 and to fund the development and commercialization of our future product candidates. Until we can generate a sufficient amount of product revenue,
if ever, we expect to finance future cash needs through public or private equity offerings, debt financings or corporate collaboration and licensing arrangements. Such funding, if needed, may not be available on favorable terms, if at all. In the
event we are unable to obtain additional capital, we may delay or reduce the scope of our current research and development programs and other expenses.

As widely reported, financial markets in the United States, Europe and Asia have been experiencing extreme disruption in recent months, including, among other things, extreme volatility in security prices, severely
diminished liquidity and credit availability, rating downgrades of certain investments and declining valuations of others. Governments have taken unprecedented actions intended to address extreme market conditions that include severely restricted
credit and declines in real estate values. Concern about the stability of the markets generally and the strength of counterparties specifically has led many lenders and institutional investors to reduce, and in some cases, cease to provide funding
to borrowers. Continued turbulence in the U.S. and international markets and economies may limit our ability to access the capital markets to meet our funding requirements.

If adequate funds are not available, we may be required to delay, reduce the scope of or eliminate one or more of our research or development programs or
our commercialization efforts. To the extent that we raise additional funds by issuing equity securities, our stockholders may experience additional significant dilution, and debt financing, if available, may involve restrictive covenants. To the
extent that we raise additional funds through collaboration and licensing arrangements, it may be necessary to relinquish some rights to our technologies or our product candidates or to grant licenses on terms that may not be favorable to us. We may
seek to access the public or private capital markets whenever conditions are favorable, even if we do not have an immediate need for additional capital at that time.

Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as
a result of a number of factors, including the factors discussed elsewhere in this Risk Factors section. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner
than we currently expect. Our future funding requirements will depend on many factors, including, but not limited to:



| |  |  | the scope, rate of progress and cost of our clinical trials and other research and development activities;
| | - |  | ----------------------------------------------------------------------------------------------------------



| |  |  | the costs and timing of regulatory approval;
| | - |  | --------------------------------------------



| |  |  | the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;
| | - |  | -------------------------------------------------------------------------------------------------------------------



| |  |  | the effect of competing technological and market developments;
| | - |  | --------------------------------------------------------------



| |  |  | the terms and timing of any collaboration, licensing or other arrangements that we may establish, including our collaboration with AstraZeneca;.
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | the cost and timing of completion of clinical and commercial-scale outsourced manufacturing activities; and
| | - |  | -----------------------------------------------------------------------------------------------------------



| |  |  | the costs of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval.
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------

We have entered into a license agreement with AstraZeneca pursuant to which we may receive certain milestones and reimbursement for
development expenses prior to commercialization of UDB, and we will not receive all of these amounts if AstraZeneca chooses to terminate the license agreement under certain circumstances.

Our license agreement with AstraZeneca for UDB provided for a $35 million milestone payment upon the successful achievement of specified primary endpoint
and safety results for our initial Phase 3 clinical trial, as well as reimbursement of costs incurred by us in connection with future UDB development activities performed by us, as set forth in a development plan we have agreed on with AstraZeneca.
In addition, upon the occurrence of certain events and conditions, we are eligible to receive up to $240 million in other potential development and regulatory milestones. In February 2009, we announced top-line results from our first Phase 3 trial
of UDB, indicating that the trial did not meet its co-primary endpoints in either of the two doses evaluated when compared to placebo. Our failure to meet the co-primary endpoints in our initial Phase 3 clinical trial gives AstraZeneca the right to
terminate the agreement or continue with the collaboration without paying the $35 million milestone. AstraZeneca has 60 days from deemed receipt of the complete data package from our initial Phase 3 clinical trial to decide whether to terminate the
agreement. In the event that AstraZeneca terminates our agreement under these circumstances, we may not have adequate resources to continue with our Phase 3 program for UDB, or with our Phase 3 program for MAP0004, or both, without raising further
funding.



26



---

##### Table of Contents

Risks Relating to the Development, Regulatory Approval and

Commercialization of Our Product Candidates

We are
largely dependent on the success of our two most advanced product candidates, UDB and MAP0004, and we cannot be certain that either of these product candidates will receive regulatory approval.

We have invested a significant portion of our efforts and financial resources in the development of our two most advanced product candidates, UDB and
MAP0004. Our ability to generate product revenue, which we do not expect will occur for at least the next several years, if ever, will depend heavily on the successful development and regulatory approval of these product candidates. We may have
inadequate financial or other resources to advance these product candidates through the clinical trial process, depending on the requirements of the FDA. We are conducting Phase 3 clinical development programs for UDB and MAP0004. In February 2009,
we announced top-line results from our first Phase 3 trial of UDB, indicating that the trial did not meet its co-primary endpoints in either dose evaluated when compared to placebo. Our clinical development programs for UDB and MAP0004 may not
lead to regulatory approval from the FDA and similar foreign regulatory agencies if we fail to demonstrate that the product candidates are safe and effective in our planned clinical trials, and we may therefore fail to commercialize any product
candidates. Any failure to obtain regulatory approval of UDB and MAP0004 would have a material and adverse impact on our business.

We
currently have no approved drug products for sale and we cannot guarantee that we will ever have marketable drug products. The research, testing, manufacturing, labeling, approval, selling, marketing and distribution of drug products are subject to
extensive regulation by the FDA and other regulatory authorities in the United States and other countries, with regulations differing from country to country. We are not permitted to market our product candidates in the United States until we
receive approval of a new drug application, or an NDA, from the FDA for each product candidate. We have not submitted an NDA or received marketing approval for any of our product candidates. Obtaining approval of an NDA is a lengthy, expensive and
uncertain process.

We will depend on our collaboration with AstraZeneca to complete the development and commercialization of our UDB product candidate
and we may enter into additional collaborations with third parties to develop and commercialize some of our other product candidates, including MAP0004. These collaborations may place the development of our product candidates outside our control,
may require us to relinquish important rights or may otherwise be on terms unfavorable to us.

In December 2008, we entered into
an exclusive collaboration with AstraZeneca for the development and commercialization of UDB worldwide. We may enter into additional collaborations with third parties to develop and commercialize some of our other product candidates, including
MAP0004. Our dependence on AstraZeneca for the development and commercialization of UDB subjects us to, and dependence on future partners for development and commercialization of our other product candidates will subject us to, a number of risks,
including:



| |  |  | we may not be able to control the amount and timing of resources that our partners may devote to the development or commercialization of product candidates or to
their marketing and distribution;
| | - |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | partners may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or
conduct new clinical trials or require a new formulation of a product candidate for clinical testing;
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | disputes may arise between us and our partners that result in the delay or termination of the research, development or commercialization of our product candidates
or that result in costly litigation or arbitration that diverts managements attention and resources;
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | partners may experience financial difficulties;
| | - |  | -----------------------------------------------



| |  |  | partners may not properly maintain or defend our intellectual property rights, or may use our proprietary information, in such a way as to invite litigation that
could jeopardize or invalidate our intellectual property rights or proprietary information or expose us to potential litigation;
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | business combinations or significant changes in a partners business strategy may also adversely affect a partners willingness or ability to complete its
obligations under any arrangement;
| | - |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | a partner could independently move forward with a competing product candidate developed either independently or in collaboration with others, including our
competitors; and
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------



27



---

##### Table of Contents

| |  |  | the collaborations with our partners may be terminated or allowed to expire, which would delay the development and may increase the cost of developing our product
candidates.
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

For example, we are jointly developing UDB with AstraZeneca in the United States. AstraZeneca will lead the
registration of UDB in the United States and has rights to commercialize UDB in the United States and to develop and commercialize UDB worldwide. We cannot control the process for securing regulatory approvals for UDB or the amount and timing of
resources that AstraZeneca may devote to the development or commercialization of UDB, or to its marketing and distribution. In addition, AstraZeneca can continue to commercialize Pulmicort Respules, and could, after a period of three years after the
first commercial sale of UDB in the United States, direct its development and marketing resources to the development or commercialization of competitive products, which could delay or impair the commercialization of UDB and harm our business.

Delays in the commencement, enrollment and completion of clinical testing could result in increased costs to us and delay or limit our ability to
obtain regulatory approval for our product candidates.

Delays in the commencement, enrollment and completion of clinical testing could
significantly affect our product development costs. We do not know whether planned clinical trials for UDB and MAP0004 will begin on time or be completed on schedule, if at all. The commencement and completion of clinical trials requires us to
identify and maintain a sufficient number of trial sites, many of which may already be engaged in other clinical trial programs for the same indication as our product candidates or may be required to withdraw from our clinical trial as a result of
changing standards of care or may become ineligible to participate in clinical studies. The commencement, enrollment and completion of clinical trials can be delayed for a variety of other reasons, including delays related to:



| |  |  | reaching agreements on acceptable terms with prospective contract research organizations, or CROs, and trial sites, the terms of which can be subject to extensive
negotiation and may vary significantly among different CROs and trial sites;
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | obtaining regulatory approval to commence a clinical trial;
| | - |  | -----------------------------------------------------------



| |  |  | obtaining institutional review board, or IRB, approval to conduct a clinical trial at numerous prospective sites;
| | - |  | -----------------------------------------------------------------------------------------------------------------



| |  |  | recruiting and enrolling patients to participate in clinical trials for a variety of reasons, including meeting the enrollment criteria for our study and
competition from other clinical trial programs for the same indication as our product candidates;
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | retaining patients who have initiated a clinical trial but may be prone to withdraw due to the treatment protocol, lack of efficacy, personal issues or side effects
from the therapy or who are lost to further follow-up;
| | - |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | maintaining and supplying clinical trial material on a timely basis;
| | - |  | --------------------------------------------------------------------



| |  |  | complying with design protocols of any applicable SPAs; and
| | - |  | -----------------------------------------------------------



| |  |  | collecting, analyzing and reporting final data from the clinical trials.
| | - |  | ------------------------------------------------------------------------

In addition, a clinical trial may be suspended or terminated by us, the FDA or other regulatory authorities due to a number of factors, including:



| |  |  | failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;
| | - |  | -----------------------------------------------------------------------------------------------------------



| |  |  | inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities resulting in the imposition of a clinical hold;
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | unforeseen safety issues or any determination that a trial presents unacceptable health risks; and
| | - |  | --------------------------------------------------------------------------------------------------



| |  |  | lack of adequate funding to continue the clinical trial, including the incurrence of unforeseen costs due to enrollment delays, requirements to conduct additional
trials and studies and increased expenses associated with the services of our CROs and other third parties.
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

If we are
required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, particularly for our UDB and MAP0004 product candidates, we may be delayed in obtaining, or may not be able to
obtain, marketing approval for these product candidates. We currently are conducting Phase 3 clinical programs for UDB and MAP0004, and will need to conduct additional Phase 3 and Phase 2 clinical trials in order to obtain regulatory approval for
these product candidates. We may not be able to obtain approval for indications that are as broad as intended or we may obtain approval for indications different than those indications for which we seek approval. Furthermore we may not be able to
obtain approval for any of our product candidates.

Additionally, changes in regulatory requirements and guidance may occur and we may need
to amend clinical trial protocols to reflect these changes with appropriate regulatory authorities. Amendments may require us to resubmit our clinical trial protocols to IRBs for re-examination, which may impact the costs, timing or successful
completion of a clinical trial. If we experience delays in the



28



---

##### Table of Contents

completion of, or if we terminate, our clinical trials, the commercial prospects for our product candidates will be harmed, and our ability to generate
product revenues will be delayed. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Even if we
are able to ultimately commercialize our product candidates, other therapies for the same or similar indications may have been introduced to the market and established a competitive advantage.

Because the results of earlier clinical trials are not necessarily predictive of future results, UDB, MAP0004 or any other product candidate advanced into clinical
trials may not have favorable results in later clinical trials or receive regulatory approval.

Success in pre-clinical studies and
early clinical trials does not ensure that later clinical trials will generate adequate data to demonstrate the efficacy and safety of the investigational drug. A number of companies in the pharmaceutical industry, including those with greater
resources and experience, have suffered significant setbacks in Phase 3 clinical trials, even after seeing promising results in earlier clinical trials.

We initiated a Phase 3 clinical program for UDB in January 2008 and initiated a Phase 3 clinical program for MAP0004 in July 2008. We have completed enrollment in both trials. In February 2009, we announced top-line
results from our first Phase 3 trial of UDB, indicating that the trial did not meet its co-primary endpoints, asthma control as assessed by changes from baseline in nighttime and daytime composite symptom scores, in the two doses evaluated when
compared to placebo. In order to obtain regulatory approval for UDB and MAP0004, we will need to conduct additional Phase 3 and Phase 2 clinical trials. The data collected from our clinical trials may not be adequate to support regulatory approval
of UDB, MAP0004 or any of our other product candidates. Despite the results reported in earlier clinical trials for our product candidates, we do not know whether any Phase 3 or other clinical programs we may conduct will demonstrate adequate
efficacy and safety to result in regulatory approval to market our product candidates. In addition, the Phase 2 clinical trial of UDB compared two doses of UDB, at 0.135 mg and 0.25 mg administered twice a day. The study showed that 0.135 mg of UDB
produced a statistically significant reduction in Nighttime and Daytime Composite Symptom Score, a measure of asthma severity, when compared to placebo, but the 0.25 mg dose was not significantly better than placebo in Nighttime and Daytime
Composite Symptom Score. In our first Phase 3 clinical trial for UDB, patients were randomized and given 0.25 mg UDB, 0.135 mg UDB or placebo to evaluate changes in Nighttime and Daytime Composite Symptom Score. Our analysis of top-line data in our
initial Phase 3 clinical trial indicated that UDB failed to demonstrate statistically significant improvements in asthma control in either the 0.135 mg dose or the 0.25 mg dose when compared with placebo. We may not demonstrate statistically
significant efficacy for either dose in any future trial, in which case we would not receive regulatory approval for either dose. Also, we may only demonstrate statistically significant efficacy for the 0.25 mg dose or the 0.135 mg dose, which could
make it difficult to receive regulatory approval for either or both doses.

If clinical trials of our UDB or MAP0004 product candidates or future
product candidates do not produce results necessary to support regulatory approval in the United States or elsewhere or show undesirable side effects, we will be unable to commercialize these products.

To receive regulatory approval for the commercial sale of UDB, MAP0004 or any other product candidates, we must conduct adequate and well-controlled
clinical trials to demonstrate efficacy and safety in humans. Clinical testing is expensive, takes many years and has an uncertain outcome. Clinical failure can occur at any stage of the testing. Our clinical trials may produce negative or
inconclusive results. For instance, in our initial Phase 3 clinical trial for UDB, top-line results indicated that the trial failed to meet the primary endpoints. In such cases, we may decide, or regulators may require us, to conduct additional
clinical and/or non-clinical testing, or we may decide not to pursue further development of a product candidate. In addition, the results of our clinical trials may show that our product candidates may cause undesirable side effects, which could
interrupt, delay or halt clinical trials, resulting in the denial of regulatory approval by the FDA and other regulatory authorities.

In
light of widely publicized events concerning the safety risk of certain drug products, regulatory authorities, members of Congress, the Government Accounting Office, medical professionals and the general public have raised concerns about potential
drug safety issues. These events have resulted in the withdrawal of drug products, revisions to drug labeling that further limit use of the drug products and establishment of risk management programs that may, for instance, restrict distribution of
drug products. The increased attention to drug safety issues may result in a more cautious approach by the FDA to clinical trials. Data from clinical trials may receive greater scrutiny with respect to safety, which may make the FDA or other
regulatory authorities more likely to terminate clinical trials before completion, or require longer or additional clinical trials that may result in substantial additional expense and a delay or failure in obtaining approval or approval for a more
limited indication than originally sought.

Our failure to adequately demonstrate the efficacy and safety of UDB, MAP0004 or any other
product candidates would prevent regulatory approval and, ultimately, the commercialization of that product candidate. In our initial Phase 3 clinical trial for UDB, patients were randomized and given 0.25 mg UDB, 0.135 mg UDB or placebo to evaluate
changes in Nighttime and Daytime Composite Symptom Scores. Top-line results indicated that the trial did not meet its co-primary endpoints in either dose evaluated when compared to placebo. In addition, the Phase 2 clinical trial of UDB compared two
doses of UDB at 0.135 mg and 0.25 mg administered twice a day. The study showed that 0.135 mg of UDB produced a statistically significant reduction in Nighttime and



29



---

##### Table of Contents

Daytime Composite Symptom Score when compared with placebo, but the 0.25 mg dose was not significantly better than placebo in Nighttime and Daytime Composite
Symptom Score. If we are unable to show a statistically significant reduction in Nighttime and Daytime Composite Symptom Score at both doses, we will not be able to obtain regulatory approval for either dose of our UDB product candidate. If we are
able to show a statistically significant reduction in Nighttime and Daytime Composite Symptom Scores at the 0.135 mg dose, but not the 0.25 mg dose, we may only obtain approval for our UDB product candidate at the single 0.135 mg dose, thereby
potentially limiting our sales opportunities, or may not obtain approval of either dose.

All of our product candidates in development require
regulatory review and approval prior to commercialization. Any delay in the regulatory review or approval of any of our product candidates in development will harm our business.

All of our product candidates in development require regulatory review and approval prior to commercialization. Any delays in the regulatory review or
approval of our product candidates in development would delay market launch, increase our cash requirements and result in additional operating losses. We will rely on AstraZeneca to submit an NDA in the United States and to obtain approval for UDB
in the United States and in other countries worldwide in which AstraZeneca chooses to seek regulatory approval.

The process of obtaining
FDA and other required regulatory approvals, including foreign approvals, often takes many years and can vary substantially based upon the type, complexity and novelty of the products involved. Furthermore, this approval process is extremely
complex, expensive and uncertain. We or our partners may not be able to maintain our proposed schedules for the submission of any NDA in the United States or any marketing approval application or other foreign applications for any of our products.
If we or our partners submit any NDA, including any amended NDA or supplemental NDA, to the FDA seeking marketing approval for any of our product candidates, the FDA must decide whether to either accept or reject the submission for filing. We cannot
be certain that any of these submissions will be accepted for filing and reviewed by the FDA, or that our marketing approval application submissions to any other regulatory authorities will be accepted for filing and review by those authorities. We
cannot be certain that we or our partners will be able to respond to any regulatory requests during the review period in a timely manner without delaying potential regulatory action. We also cannot be certain that any of our product candidates will
receive favorable recommendation from any FDA advisory committee or foreign regulatory bodies or be approved for marketing by the FDA or foreign regulatory authorities. In addition, delays in approvals or rejections of marketing applications may be
based upon many factors, including regulatory requests for additional analyses, reports, data and/or studies, regulatory questions regarding data and results, changes in regulatory policy during the period of product development and/or the emergence
of new information regarding our products or other products.

Data obtained from pre-clinical studies and clinical trials are subject to
different interpretations, which could delay, limit or prevent regulatory review or approval of any of our products. In addition, as a routine part of the evaluation of any potential drug, clinical studies are generally conducted to assess the
potential for drug-to-drug interactions that could impact potential product safety. At this point in time, we have not been requested to perform drug-to-drug interaction studies, but any such request may delay any potential product approval and will
increase our expenses associated with our clinical programs. Furthermore, regulatory attitudes towards the data and results required to demonstrate safety and efficacy can change over time and can be affected by many factors, such as the emergence
of new information, including on other products, changing policies and agency funding, staffing and leadership. We cannot be sure whether future changes to the regulatory environment will be favorable or unfavorable to our business prospects.

In addition, the environment in which our regulatory submissions may be reviewed changes over time. For example, average review times at
the FDA for marketing approval applications have fluctuated over the last ten years, and we cannot predict the review time for any of our submissions with any regulatory authorities. In addition, review times can be affected by a variety of factors,
including budget and funding levels and statutory, regulatory and policy changes.

While we have negotiated an SPA with the FDA for our first Phase 3
clinical trial of MAP0004 for the potential treatment of migraine, the achievement of pre-specified trial results under the SPA does not guarantee any particular outcome from regulatory review of the study or the product candidate.

The FDAs SPA process creates a written agreement between the sponsoring company and the FDA regarding clinical trial design and other clinical
trial issues that can be used to support approval of a product candidate. The SPA is intended to provide assurance that if pre-specified trial results are achieved, they may serve as the primary basis for an efficacy claim in support of an NDA.
However, the SPA agreement is not a guarantee of an approval of a product or any permissible claims about the product. In particular, the SPA is not binding on the FDA if public health concerns unrecognized at the time of the SPA agreement is
entered into become evident, other new scientific concerns regarding product safety or efficacy arise or if the sponsor company fails to comply with the agreed upon trial protocols. In January 2008, we announced that we reached agreement with the
FDA on a SPA for the first Phase 3 clinical trial of our MAP0004 product candidate for the potential treatment of migraine. We cannot assure you that the Phase 3 clinical trial will be successful. In addition, we do not know how the FDA will
interpret the commitments under the SPA agreement, how it will interpret the data and results or whether it will approve our MAP0004 product candidate for the treatment of migraine. As a result, we cannot guarantee any particular outcome from
regulatory review of the first MAP0004 Phase 3 trial.



30



---

##### Table of Contents

We may not be able to rely on Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act, which could result in
a longer development program and more costly trials than we anticipate.

We may not be able to seek FDA marketing approval of our
product candidates under Section 505(b)(2) of the FFDCA. Section 505(b)(2), if applicable to us, would allow an NDA we file with the FDA to rely in part on data in the public domain or the FDAs prior conclusions regarding the safety
and effectiveness of approved compounds, which could expedite the development program for our product candidates by potentially decreasing the overall scope of work we must do ourselves. If we are unable to rely on Section 505(b)(2), the
development program for our product candidates would be longer than we expect, and we would also have to conduct more costly trials than we anticipate.

If any of our product candidates for which we or our partners receive regulatory approval do not achieve broad market acceptance, the revenues that we generate from their sales will be limited.

The commercial success of our product candidates for which we or our partners, such as AstraZeneca, obtain marketing approval from the FDA or other
regulatory authorities will depend upon the acceptance of these products among physicians, the medical community, patients, and coverage and reimbursement of them by third-party payors, including government payors. The degree of market acceptance of
any of our approved products will depend on a number of factors, including:



| |  |  | a products FDA-approved labeling as well as limitations or warnings contained in the labeling;
| | - |  | -----------------------------------------------------------------------------------------------



| |  |  | changes in the standard of care for the targeted indications for any of our product candidates, which could reduce the marketing impact of any claims that we could
make following FDA approval;
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | limitations inherent in the approved indication for any of our product candidates compared to more commonly understood or addressed medical conditions;
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | lower demonstrated efficacy and a less favorable safety profile compared to other products;
| | - |  | -------------------------------------------------------------------------------------------



| |  |  | prevalence and severity of adverse effects;
| | - |  | -------------------------------------------



| |  |  | ineffective marketing and distribution efforts;
| | - |  | -----------------------------------------------



| |  |  | lack of availability of reimbursement from managed care plans and other third-party payors;
| | - |  | -------------------------------------------------------------------------------------------



| |  |  | lack of cost-effectiveness;
| | - |  | ---------------------------



| |  |  | timing of market introduction and perceived effectiveness of competitive products;
| | - |  | ----------------------------------------------------------------------------------



| |  |  | availability of alternative therapies, including generics, at similar or lower costs;
| | - |  | -------------------------------------------------------------------------------------



| |  |  | patients potential preferences to take oral medications over inhaled medications; and
| | - |  | --------------------------------------------------------------------------------------



| |  |  | potential product liability claims.
| | - |  | -----------------------------------

Our and our partners ability to effectively promote and sell our product candidates in the marketplace will also depend on pricing and cost effectiveness, including our and our partners ability to manufacture a product at a
competitive price. We will also need to demonstrate acceptable evidence of safety and efficacy and may need to demonstrate relative convenience and ease of administration. Market acceptance could be further limited depending on the prevalence and
severity of any expected or unexpected adverse side effects associated with our product candidates. If our product candidates are approved but do not achieve an adequate level of acceptance by physicians, health care payors and patients, we may not
generate sufficient revenue from these products, and we may not become or remain profitable. In addition, our and our partners efforts to educate the medical community and third-party payors on the benefits of our product candidates may
require significant resources and may never be successful. If our approved drugs fail to achieve market acceptance, we will not be able to generate significant revenue, if any.

We have never marketed a drug before, and if we are unable to establish an effective and focused sales force and marketing infrastructure, we will not be able to commercialize our product candidates successfully.

We plan to market or co-promote our products where appropriate and build our own focused sales force in the United States. We
currently do not have significant internal sales, distribution and marketing capabilities. AstraZeneca will support and fund the establishment of our focused sales force to co-promote UDB in the United States for a certain period of time after
product launch. In order to commercialize MAP0004, we intend to develop a focused sales force and marketing capabilities in the United States. The development of a focused sales and marketing infrastructure for our domestic operations will require
substantial resources, will be expensive and time consuming and could negatively impact our commercialization efforts, including delay of any product launch. Many of these costs will be incurred in advance of notice to us that any of our product
candidates has been approved. In addition, we may not be able to hire a focused sales force in the United States that is sufficient in size or has adequate expertise in the medical markets that we intend to target, including pediatrics and
neurology. If we are unable to establish our focused sales force and marketing capability for our most advanced product candidates, we may not be able to generate any product revenue, may generate increased expenses and may never become profitable.



31



---

##### Table of Contents

We expect intense competition with respect to our existing and future product candidates.

The pharmaceutical industry is highly competitive, with a number of established, large pharmaceutical companies, as well as many smaller companies. Many
of these companies have greater financial resources, marketing capabilities and experience in obtaining regulatory approvals for product candidates. There are many pharmaceutical companies, biotechnology companies, public and private universities,
government agencies and research organizations actively engaged in research and development of products which may target the same indications as our product candidates. We expect any future products we develop to compete on the basis of, among other
things, product efficacy and safety, time to market, price, extent of adverse side effects and convenience of treatment procedures. One or more of our competitors may develop products based upon the principles underlying our proprietary technologies
earlier than us, obtain approvals for such products from the FDA more rapidly than us or develop alternative products or therapies that are safer, more effective and/or more cost effective than any products developed by us.

Competitors may seek to develop alternative formulations of our product candidates that address our targeted indications. The commercial opportunity for
our product candidates could be significantly harmed if competitors are able to develop alternative formulations outside the scope of our products. Compared to us, many of our potential competitors have substantially greater:



| |  |  | capital resources;
| | - |  | ------------------



| |  |  | research and development resources, including personnel and technology;
| | - |  | -----------------------------------------------------------------------



| |  |  | clinical trial experience;
| | - |  | --------------------------



| |  |  | regulatory experience;
| | - |  | ----------------------



| |  |  | expertise in prosecution of intellectual property rights;
| | - |  | ---------------------------------------------------------



| |  |  | manufacturing and distribution experience; and
| | - |  | ----------------------------------------------



| |  |  | sales and marketing resources and experience.
| | - |  | ---------------------------------------------

As a result of these factors, our competitors may obtain regulatory approval of their products more rapidly than we are able to or may obtain patent protection or other intellectual property rights that limit our
ability to develop or commercialize our product candidates. Our competitors may also develop drugs that are more effective, useful and less costly than ours and may also be more successful than us in manufacturing and marketing their products.

The pediatric asthma market is extremely competitive and may adversely affect our ability to commercialize UDB.

If approved for the treatment of asthma in children, we anticipate that UDB would compete with other marketed asthma therapeutics, including inhaled
corticosteroids and leukotriene modifiers, and may compete with products currently under development by both large and small companies. Until November 2008, conventional nebulized budesonide was the only inhaled corticosteroid approved by the FDA
for treating asthma in children under four years old. Conventional nebulized budesonide is available from our partner AstraZeneca as Pulmicort Respules. Pulmicort Respules was introduced in the United States in 2000, and annual sales have grown to
approximately $900 million in the United States and approximately $1.2 billion worldwide in 2007 according to data published by IMS Health. Leukotriene modifiers are an alternative to inhaled corticosteroids for asthmatic children. We believe that
prescriptions of Merck & Co., Inc.s Singulair, the leading leukotriene modifier, for children up to eight years of age generated approximately $900 million in sales in 2007. In addition to marketed asthma therapies, there are several
inhaled corticosteroid product candidates under development by large pharmaceutical companies, such as GlaxoSmithKline plc, or GlaxoSmithKline, and other smaller companies, that could potentially be used to treat asthma in children.

We may also face competition from generic entry of conventional nebulized budesonide. For example, in November 2008 the FDA approved an abbreviated new
drug application, or ANDA, filed by Teva Pharmaceutical Industries Ltd, or Teva, for conventional nebulized budesonide based on Pulmicort Respules. Under an agreement with AstraZeneca, Teva has obtained a license to AstraZeneca patents relating to
Pulmicort Respules and may begin selling its generic version of conventional nebulized budesonide in December 2009. In March 2009, the FDA approved an ANDA filed by Apotex for conventional nebulized budesonide based on Pulmicort Respules.
AstraZeneca has filed a lawsuit against Apotex alleging that the generic product infringes patents held by AstraZeneca. Although we believe a generic version of conventional nebulized budesonide could not be substituted for UDB, a generic version of
conventional nebulized budesonide may be more quickly adopted by health insurers and patients than UDB. Financial pressure to use generic products and uncertainty of reimbursement for single source alternatives, such as UDB, may encourage the use of
a generic product over UDB.



32



---

##### Table of Contents

The migraine market is extremely competitive which may negatively impact our ability to commercialize MAP0004.

If approved for the treatment of acute migraine, we anticipate that MAP0004 would compete against other marketed migraine therapeutics and
may compete with products currently under development by both large and small companies. The majority of marketed prescription products for treatment of migraine are in the triptan class. The largest selling triptan is Imitrex from GlaxoSmithKline,
with 2007 sales of approximately $1.2 billion in the United States and $1.6 billion worldwide, according to data published by IMS Health. There are at least six other branded triptan therapies being sold by pharmaceutical companies. Alternative
formulations of triptans are available that may have faster onset of action than solid oral dosage forms. Alternative formulations of DHE include Migranal, which is nasally delivered. In addition to the marketed migraine therapeutics, there are
product candidates under development by large pharmaceutical companies, such as Merck & Co., Inc., and other smaller companies, that could potentially be used to treat migraine and compete with MAP0004.

In addition, we may face competition from generic sumatriptan, the active ingredient in Imitrex. The FDA has approved generic versions of sumatriptan.
Although we believe generic sumatriptan could not be substituted for MAP0004, a generic version of sumatriptan may be more quickly adopted by health insurers and patients than MAP0004. Financial pressure to use generic products and uncertainty of
reimbursement for single source alternatives, such as MAP0004, may encourage the use of a generic product over MAP0004.

If our patients are unable to
obtain coverage of or sufficient reimbursement for our products, it is unlikely that our products will be widely used.

Successful
sales of our products depend on the availability of adequate coverage and reimbursement from third-party payors. Healthcare providers that purchase medicine or medical products for treatment of their patients generally rely on third-party payors to
reimburse all or part of the costs and fees associated with the products. Adequate coverage and reimbursement from governmental payors, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. Patients are unlikely
to use our products if they do not receive reimbursement adequate to cover the cost of our products.

In addition, the market for our
future products will depend significantly on access to third-party payors drug formularies, or lists of medications for which third-party payors provide coverage and reimbursement. Industry competition to be included in such formularies
results in downward pricing pressures on pharmaceutical companies. Third-party payors may refuse to include a particular branded drug in their formularies when a generic equivalent is available.

All third-party payors, whether governmental or commercial, whether inside the United States or outside, are developing increasingly sophisticated
methods of controlling healthcare costs. In addition, in the United States, no uniform policy of coverage and reimbursement for medical technology exists among all these payors. Therefore, coverage of and reimbursement for medical products can
differ significantly from payor to payor.

Further, we believe that future coverage and reimbursement may be subject to increased
restrictions both in the United States and in international markets. Third-party coverage and reimbursement for our products may not be available or adequate in either the United States or international markets, limiting our ability to sell our
products on a profitable basis.

Even if our product candidates receive regulatory approval in the United States, we or our partners may never receive
approval or commercialize our products outside of the United States.

In order to market and commercialize any products outside of the
United States, we and our partners must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Approval procedures vary among countries and can involve additional pre-clinical studies
and clinical trials and additional administrative review periods. For example, European regulatory authorities generally require clinical testing comparing the efficacy of the new drug to an existing drug prior to granting approval. The time
required to obtain approval in other countries might differ from that required to obtain FDA approval. The regulatory approval process in other countries may include all of the risks detailed above regarding FDA approval in the United States, as
well as other risks. Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in other countries.
Failure to obtain regulatory approval in other countries or any delay or setback in obtaining such approval could have the same adverse effects detailed above regarding FDA approval in the United States. As described above, such effects include the
risks that our product candidates may not be approved for all indications requested, which could limit the uses of our product candidates and have an adverse effect on product sales and potential royalties, and that such approval may be subject to
limitations on the indicated uses for which the product may be marketed or require costly, post-marketing follow-up studies.

Our product candidates may
have undesirable side effects and cause our approved drugs to be taken off the market.

If either or both of our most advanced product
candidates receives marketing approval and we or others later identify undesirable side effects caused by such products:



| |  |  | regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies;
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------



33



---

##### Table of Contents

| |  |  | regulatory authorities may withdraw their approval of the product and require us to take our approved drug off the market;
| | - |  | --------------------------------------------------------------------------------------------------------------------------



| |  |  | we may be required to change the way the product is administered, conduct additional clinical trials or change the labeling of the product;
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | we may have limitations on how we promote our drugs;
| | - |  | ----------------------------------------------------



| |  |  | sales of products may decrease significantly;
| | - |  | ---------------------------------------------



| |  |  | we may be subject to litigation or product liability claims; and
| | - |  | ----------------------------------------------------------------



| |  |  | our reputation may suffer.
| | - |  | --------------------------

Any of
these events could prevent us from achieving or maintaining market acceptance of the affected product or could substantially increase our commercialization costs and expenses, which in turn could delay or prevent us from generating significant
revenues from its sale.

Even if our product candidates receive regulatory approval, we and our partners may still face future development and
regulatory difficulties.

Even if U.S. regulatory approval is obtained, the FDA may still impose significant restrictions on a
products indicated uses or marketing or impose ongoing requirements for potentially costly post-approval studies. Given the number of recent high profile adverse safety events with certain drug products, the FDA may require, as a condition of
approval, costly risk management programs which may include safety surveillance, restricted distribution and use, patient education, enhanced labeling, special packaging or labeling, expedited reporting of certain adverse events, pre-approval of
promotional materials and restrictions on direct-to-consumer advertising. Furthermore, heightened Congressional scrutiny on the adequacy of the FDAs drug approval process and the agencys efforts to assure the safety of marketed drugs has
resulted in the proposal of new legislation addressing drug safety issues. If enacted, any new legislation could result in delays or increased costs during the period of product development, clinical trials and regulatory review and approval, as
well as increased costs to assure compliance with any new post-approval regulatory requirements. Any of these restrictions or requirements could force us to conduct costly studies or increase the time for us to become profitable. For example, any
labeling approved for UDB, MAP0004 or any other product candidates may include a restriction on the term of its use, or it may not include one or more of our intended indications. The FDA historically has required that labeling for products
containing DHE include a contraindication for use in women who are, or who may become, pregnant. Although we believe that this contraindication is not applicable to our formulation of DHE, the FDA may disagree and require the MAP0004 labeling to
carry this contraindication.

Our product candidates will also be subject to ongoing FDA requirements for the labeling, packaging, storage,
advertising, promotion, record-keeping and submission of safety and other post-market information on the drug. In addition, approved products, manufacturers and manufacturers facilities are subject to continual review and periodic inspections.
If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions
on that product or us, including requiring withdrawal of the product from the market. If our product candidates fail to comply with applicable regulatory requirements, or fail to be made in compliance with applicable regulatory requirements such as
current Good Manufacturing Practices, or cGMPs, a regulatory agency may:



| |  |  | issue warning letters;
| | - |  | ----------------------



| |  |  | require us to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due dates for specific
actions and penalties for noncompliance;
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | impose other civil or criminal penalties;
| | - |  | -----------------------------------------



| |  |  | suspend regulatory approval;
| | - |  | ----------------------------



| |  |  | suspend any ongoing clinical trials;
| | - |  | ------------------------------------



| |  |  | refuse to approve pending applications or supplements to approved applications filed by us;
| | - |  | -------------------------------------------------------------------------------------------



| |  |  | impose restrictions on operations, including costly new manufacturing requirements; or
| | - |  | --------------------------------------------------------------------------------------



| |  |  | seize or detain products or require a product recall.
| | - |  | -----------------------------------------------------



34



---

##### Table of Contents

We or our partners will need to obtain FDA approval of the proposed product names for our product candidates and any
failure or delay associated with such approval may adversely impact our business.

Any name we or our partners intend to use for our
product candidates will require approval from the FDA regardless of whether we or our partners have secured a formal trademark registration from the U.S. Patent and Trademark Office. The FDA typically conducts a rigorous review of proposed product
names, including an evaluation of potential for confusion with other product names. The FDA may also object to a product name if it believes the name inappropriately implies medical claims. If the FDA objects to our product names, we may be required
to adopt an alternative name for our product candidates. If we or our partners adopt an alternative name, we or our partners would lose the benefit of our existing trademark applications and may be required to expend significant additional resources
in an effort to identify a suitable product name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. We or our partners may be unable to build a successful brand
identity for a new trademark in a timely manner or at all, which would limit our ability to commercialize our product candidates.

Guidelines and
recommendations published by various organizations may affect the use of our products.

Government agencies issue regulations and
guidelines directly applicable to us and to our products. In addition, professional societies, practice management groups, private health/science foundations and organizations involved in various diseases from time to time publish guidelines or
recommendations to the medical and patient communities. These various sorts of recommendations may relate to such matters as product usage, dosage, route of administration and use of related or competing therapies. For example, organizations like
Global Initiative for Asthma, or GINA, and the National Asthma Education and Prevention Program, or NAEPP, have made recommendations about therapies in the pediatric asthma market. GINA guidelines issued in 2006 and NAEPP guidelines issued in 2007
recommend the use of inhaled corticosteroids as the preferred treatment to reduce inflammation and maintain long-term control of asthma in children aged five years and younger. Changes to this recommendation or other guidelines advocating
alternative therapies could result in decreased use of our products, which may adversely affect our results of operations.

We face potential product
liability exposure and, if successful claims are brought against us, we may incur substantial liability for a product candidate and may have to limit its commercialization.

The use of our product candidates in clinical trials and the sale of any products for which we obtain marketing approval, if at all, expose us to the
risk of product liability claims. Product liability claims might be brought against us by consumers, health care providers or others using, administering or selling our products. If we cannot successfully defend ourselves against these claims, we
will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:



| |  |  | withdrawal of clinical trial participants;
| | - |  | ------------------------------------------



| |  |  | termination of clinical trial sites or entire trial programs;
| | - |  | -------------------------------------------------------------



| |  |  | costs of related litigation;
| | - |  | ----------------------------



| |  |  | substantial monetary awards to patients or other claimants;
| | - |  | -----------------------------------------------------------



| |  |  | decreased demand for our product candidates;
| | - |  | --------------------------------------------



| |  |  | impairment of our business reputation;
| | - |  | --------------------------------------



| |  |  | loss of revenues; and
| | - |  | ---------------------



| |  |  | the inability to commercialize our product candidates.
| | - |  | ------------------------------------------------------

We have obtained limited product liability insurance coverage for our clinical trials domestically and in selected foreign countries where we are conducting clinical trials. However, our insurance coverage may not
reimburse us or may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and, in the future, we may not be able to maintain insurance coverage at a reasonable
cost or in sufficient amounts to protect us against losses due to liability. We intend to expand our insurance coverage to include the sale of commercial products if we obtain marketing approval for our product candidates in development, but we may
be unable to obtain commercially reasonable product liability insurance for any products approved for marketing. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated side effects. A successful
product liability claim or series of claims brought against us could cause our stock price to fall and, if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business.

Our operations involve hazardous materials, which could subject us to significant liabilities.

Our research and development processes involve the controlled use of hazardous materials, including chemicals. Our operations produce hazardous waste
products. We cannot eliminate the risk of accidental contamination or discharge or injury from these materials. Federal, state and local laws and regulations govern the use, manufacture, storage, handling and disposal of these materials. We could be
subject to civil damages in the event of an improper or unauthorized release of, or exposure of individuals, including employees, to, hazardous materials. In addition, claimants may sue us for injury or contamination that results from our use of
these materials and our liability may exceed our total assets. We maintain insurance for the use of hazardous materials which may not be adequate to cover any claims. Compliance with environmental and other laws and regulations may be expensive and
current or future regulations may impair our research, development or production efforts.



35



---

##### Table of Contents

Our insurance policies are expensive and protect us only from some business risks, which will leave us exposed to
significant uninsured liabilities.

We do not carry insurance for all categories of risk that our business may encounter. For example,
we do not carry earthquake insurance. In the event of a major earthquake in our region, our business could suffer significant and uninsured damage and loss. Some of the policies we currently maintain include general liability, property, auto,
workers compensation, products liability and directors and officers insurance policies. Our insurance is expensive and we do not know if we will be able to maintain existing insurance with adequate levels of coverage. Any
significant uninsured liability may require us to pay substantial amounts, which would adversely affect our cash position and results of operations.

Risks Related to Our Dependence on Third Parties

We have no experience manufacturing large clinical-scale or commercial-scale
pharmaceutical products and we do not own or operate a manufacturing facility. As a result, we are dependent on numerous third parties for the manufacture of our product candidates and our supply chain, and if we experience problems with any of
these suppliers the manufacturing of our products could be delayed.

We do not own or operate manufacturing facilities for clinical or
commercial manufacture of our product candidates, which includes drug substance and drug packaging, including the components of the Tempo inhaler, the device used to administer certain of our drug candidates. We have limited personnel with
experience in drug manufacturing and we lack the capabilities to manufacture any of our product candidates on a clinical or commercial scale. We currently outsource all manufacturing and packaging of our pre-clinical and clinical product candidates
to third parties. In addition, we do not currently have all necessary agreements with third-party manufacturers for the long-term commercial supply of our product candidates. We may be unable to enter agreements for commercial supply with all
third-party manufacturers, or may be unable to do so on acceptable terms. Even if we enter into these agreements or, for those agreements that we have already entered into, the various manufacturers of each product candidate will likely be single
source suppliers to us for a significant period of time. We may not be able to establish additional sources of supply for our products prior to commercialization. Such suppliers are subject to regulatory requirements covering manufacturing, testing,
quality control and record keeping relating to our product candidates, and are subject to ongoing inspections by the regulatory agencies. Failure by any of our suppliers to comply with applicable regulations may result in long delays and
interruptions to our manufacturing capacity while we seek to secure another supplier that meets all regulatory requirements.

Reliance on
third-party manufacturers entails risks to which we would not be subject if we manufactured the product candidates ourselves, including:



| |  |  | reliance on the third parties for regulatory compliance and quality assurance;
| | - |  | ------------------------------------------------------------------------------



| |  |  | the possible breach of the manufacturing agreements by the third parties because of factors beyond our control; and
| | - |  | -------------------------------------------------------------------------------------------------------------------



| |  |  | the possibility of termination or nonrenewal of the agreements by the third parties because of our breach of the manufacturing agreement or based on their own
business priorities.
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Any of these factors could cause the delay or suspension of initiation or completion of clinical
trials, regulatory submissions, required approvals or commercialization of our products, cause us to incur higher costs and could prevent us from commercializing our product candidates successfully. Furthermore, if our contract manufacturers fail to
deliver the required commercial quantities of finished product on a timely basis and at commercially reasonable prices and we are unable to find one or more replacement manufacturers capable of production at a substantially equivalent cost, in
substantially equivalent volumes and quality and on a timely basis, we would likely be unable to meet demand for our products and we would lose potential revenue. It may take a significant period of time to establish an alternative source of supply
for our product candidates and to have any such new source approved by the FDA.

The success of commercialization of UDB, if any, depends in part on the
performance of AstraZeneca, over which we have little or no control.

Our ability to commercialize UDB, which we are developing with
AstraZeneca, and to generate royalties from UDB sales depends on AstraZenecas abilities to assist us in establishing the safety and efficacy of UDB, obtaining and maintaining regulatory approvals and achieving market acceptance of UDB once
commercialized. AstraZeneca may elect to delay or terminate development of UDB, independently commercialize Pulmicort Respules, independently develop additional drugs that could compete with UDB after the period beginning three years after the first
commercial sale of UDB in the United States or earlier if we fail to achieve specified endpoint and safety results or an alternative product has a materially better target product profile, or fail to commit sufficient resources to the marketing and
distribution of UDB. AstraZeneca may not proceed with the development and commercialization of UDB with the same degree of urgency as we would because of other priorities AstraZeneca may have. If AstraZeneca fails to perform diligently, our
potential for revenue from UDB could be dramatically reduced.



36



---

##### Table of Contents

If we are unable to establish marketing, sales and distribution collaborations with third parties, we may not be able
to commercialize MAP0004 successfully.

We plan to establish marketing, sales and distribution collaborations with third parties where
appropriate. For example, if we choose to expand the marketing and sales of MAP0004 to primary care physicians, we may establish partnerships with other companies to maximize the potential of the commercialization opportunity. Outside the United
States, we may establish commercial partnerships for MAP0004 in order to effectively reach target markets in order to maximize its commercial opportunities. We also expect to face competition in our efforts to identify appropriate collaborators or
partners to help commercialize MAP0004 in our target commercial areas. If we are unable to establish adequate marketing, sales and distribution collaborations to target primary care physicians, specialists and other large groups of prescribing
physicians within and outside the United States, then we may not be able to achieve the full commercial opportunity for MAP0004.

We may not be
successful in maintaining or establishing development collaborations, which could adversely affect our ability to develop certain of our product candidates.

Our earlier stage product portfolio includes MAP0005 and MAP0001. We have no current intention to further develop either of these earlier stage product candidates independently. Developing pharmaceutical products,
conducting clinical trials, establishing manufacturing capabilities and marketing approved products is expensive. Consequently, we may establish partnerships for further development and commercialization of these two product candidates. We expect to
face competition in seeking appropriate partners. Moreover, collaboration arrangements are complex and time consuming to negotiate, document and implement and they may require substantial resources to maintain. We may not be successful in our
efforts to establish and implement collaborations or other alternative arrangements, if any. The terms of any collaboration or other arrangement that we establish may not be favorable to us. In addition, any collaboration that we enter into may not
be successful. If we seek partners to help develop MAP0005 and MAP0001, but are unable to reach agreements with suitable partners, we may fail to commercialize the affected product or program.

Risks Relating to Our Intellectual Property

It is difficult and costly to protect our
proprietary rights, and we may not be able to ensure their protection.

Our commercial success will depend in part on obtaining and
maintaining patent protection and trade secret protection of our product candidates and the methods used to manufacture them, as well as successfully defending these patents against third-party challenges. Our ability to stop third parties from
making, using, selling, offering to sell or importing our products is dependent upon the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities.

We license certain intellectual property from third parties that covers our product candidates. We rely on certain of these third parties to file,
prosecute and maintain patent applications and otherwise protect the intellectual property to which we have a license, and we have not had and do not have primary control over these activities for certain of these patents or patent applications and
other intellectual property rights. We cannot be certain that such activities by third parties have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual
property rights. Our enforcement of certain of these licensed patents or defense of any claims asserting the invalidity of these patents would also be subject to the cooperation of the third parties.

The patent positions of pharmaceutical and biopharmaceutical companies can be highly uncertain and involve complex legal and factual questions for which
important legal principles remain unresolved. No consistent policy regarding the breadth of claims allowed in biopharmaceutical patents has emerged to date in the United States. The biopharmaceutical patent situation outside the United States
is even more uncertain. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that
may be allowed or enforced in the patents we own or to which we have a license or third-party patents. Further, if any of our patents are deemed invalid and unforceable, it could impact our ability to commercialize or license our technology.

The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not
adequately protect our rights or permit us to gain or keep our competitive advantage. For example:



| |  |  | others may be able to make compounds that are similar to our product candidates but that are not covered by the claims of our patents;
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------



| |  |  | we might not have been the first to make the inventions covered by our pending issued patents or patent applications;
| | - |  | ---------------------------------------------------------------------------------------------------------------------



| |  |  | we might not have been the first to file patent applications for these inventions;
| | - |  | ----------------------------------------------------------------------------------



| |  |  | others may independently develop similar or alternative technologies or duplicate any of our technologies;
| | - |  | ----------------------------------------------------------------------------------------------------------



37



---

##### Table of Contents

| |  |  | it is possible that our pending patent applications will not result in issued patents;
| | - |  | --------------------------------------------------------------------------------------



| |  |  | our issued patents may not provide us with any competitive advantages, or may be held invalid or unenforceable as a result of legal challenges by third parties;
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | we may not develop additional proprietary technologies that are patentable; or
| | - |  | ------------------------------------------------------------------------------



| |  |  | the patents of others may have an adverse effect on our business.
| | - |  | -----------------------------------------------------------------

We also may rely on trade secrets to protect our technology, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. Although we use
reasonable efforts to protect our trade secrets, our employees, consultants, contractors, outside scientific collaborators and other advisors may unintentionally or willfully disclose our information to competitors. Enforcing a claim that a third
party illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. Moreover, our
competitors may independently develop equivalent knowledge, methods and know-how.

We may incur substantial costs as a result of litigation or other
proceedings relating to patent and other intellectual property rights and we may be unable to protect our rights to, or use, our technology.

If we or our partners choose to go to court to stop someone else from using the inventions claimed in our patents, that individual or company has the right to ask the court to rule that these patents are invalid and/or should not be
enforced against that third party. These lawsuits are expensive and would consume time and other resources even if we were successful in stopping the infringement of these patents. In addition, there is a risk that the court will decide that these
patents are not valid and that we do not have the right to stop the other party from using the inventions. There is also the risk that, even if the validity of these patents is upheld, the court will refuse to stop the other party on the ground that
such other partys activities do not infringe our rights to these patents. In addition, the U.S. Supreme Court has recently invalidated some tests used by the U.S. Patent and Trademark Office in granting patents over the past 20 years. As a
consequence, several issued patents may be found to contain invalid claims according to the newly revised standards. Some of our own or in-licensed patents may be subject to challenge and subsequent invalidation in a re-examination proceeding before
the U.S. Patent and Trademark Office or during litigation under the revised criteria which make it more difficult to obtain patents.

Furthermore, a third party may claim that we or our manufacturing or commercialization partners are using inventions covered by the third partys patent rights and may go to court to stop us from engaging in our normal operations and
activities, including making or selling our product candidates. These lawsuits are costly and could affect our results of operations and divert the attention of managerial and technical personnel. There is a risk that a court would decide that we or
our commercialization partners are infringing the third partys patents and would order us or our partners to stop the activities covered by the patents. In addition, there is a risk that a court will order us or our partners to pay the other
party damages for having violated the other partys patents. We have agreed to indemnify certain of our commercial partners against certain patent infringement claims brought by third parties. The biotechnology industry has produced a
proliferation of patents, and it is not always clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation
is not always uniform. If we are sued for patent infringement, we would need to demonstrate that our products or methods of use either do not infringe the patent claims of the relevant patent and/or that the patent claims are invalid, and we may not
be able to do this. Proving invalidity, in particular, is difficult since it requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents.

Because some patent applications in the United States may be maintained in secrecy until the patents are issued, because patent applications in the
United States and many foreign jurisdictions are typically not published until eighteen months after filing and because publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed
patent applications for technology covered by our issued patents or our pending applications, or that we were the first to invent the technology. Our competitors may have filed, and may in the future file, patent applications covering technology
similar to ours. Any such patent application may have priority over our patent applications or patents, which could further require us to obtain rights to issued patents covering such technologies. If another party has filed a U.S. patent
application on inventions similar to ours, we may have to participate in an interference proceeding declared by the U.S. Patent and Trademark Office to determine priority of invention in the United States. The costs of these proceedings could
be substantial, and it is possible that such efforts would be unsuccessful if, unbeknownst to us, the other party had independently arrived at the same or similar invention prior to our own invention, resulting in a loss of our U.S. patent
position with respect to such inventions.

Some of our competitors may be able to sustain the costs of complex patent litigation more
effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds
necessary to continue our operations.



38



---

##### Table of Contents

If we fail to comply with our obligations in our intellectual property licenses with third parties, we could lose
license rights that are important to our business.

We are a party to a number of license agreements, including with Elan Pharma
International Limited and with Nektar Therapeutics UK Limited, pursuant to which we license key intellectual property, including intellectual property relating to our most advanced product candidates. These existing licenses impose various
diligence, milestone payment, royalty, insurance and other obligations on us. If we fail to comply with these obligations, the licensors may have the right to terminate the license, in which event we might not be able to develop or market any
product that is covered by the licensed patents. If we lose such license rights that are important to our product candidates, our business may be materially adversely affected. We may enter into additional licenses in the future and if we fail to
comply with obligations under those agreements, we could suffer similar consequences.

We may be subject to claims that our employees have wrongfully
used or disclosed alleged trade secrets of their former employers.

As is common in the biotechnology and pharmaceutical industries, we
employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that these
employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against
these claims, litigation could result in substantial costs and be a distraction to management.

Risks Related to Employee Matters and
Managing Growth

We will need to increase the size of our company, and we may experience difficulties in managing growth.

As of March 31, 2009, we had 98 full-time employees. We will need to continue to expand our managerial, operational, administrative financial and
other resources in order to manage and fund our operations and clinical trials, continue our development activities and commercialize our product candidates. To support this growth, we may hire additional employees within the next 12 months.
Our management, personnel, systems and facilities currently in place may not be adequate to support this future growth. Our need to effectively manage our operations, growth and various projects requires that we:



| |  |  | manage our Phase 3 clinical programs for UDB and MAP0004 and other additional trials effectively, which we anticipate will be conducted with numerous vendors at
numerous clinical sites; and
| | - |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | continue to improve our operational, financial and management controls, reporting systems and procedures.
| | - |  | ---------------------------------------------------------------------------------------------------------

We may be unable to successfully implement these tasks on a larger scale and, accordingly, may not achieve our development and commercialization goals.

We may not be able to manage our business effectively if we are unable to attract and retain key personnel.

We may not be able to attract or retain qualified management and scientific and clinical personnel in the future due to competition for qualified
personnel among biotechnology, pharmaceutical and other businesses, particularly in the Silicon Valley area of California. If we are not able to attract and retain necessary personnel to accomplish our business objectives, we may experience
constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.

Our industry has experienced a high rate of turnover of management personnel in recent years. We are highly dependent on the development, regulatory,
commercialization and product acquisition expertise of our senior management, particularly Timothy S. Nelson, our President and Chief Executive Officer, and Thomas A. Armer, our co-founder and Chief Scientific Officer. If we lose one or more of
these key employees, our ability to implement our business strategy successfully could be seriously harmed. Replacing key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry
with the breadth of skills and experience required to develop, obtain regulatory approval of and commercialize products successfully. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate
these additional key personnel.

In addition, we have scientific and clinical advisors who assist us in our product development and
clinical strategies. These advisors are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability to us, or may have arrangements with other companies to assist in the
development of products that may compete with ours. Because our business depends on certain key personnel and advisors, the loss of such personnel and advisors could weaken our management team and we may experience difficulty in attracting and
retaining qualified personnel and advisors.

Our executive officers and certain key personnel are critical to our business and have limited experience
in running a public company and are new to their current roles.

As a public company, we are highly dependent on the expertise of our
senior management, particularly our Chief Executive Officer and Chief Financial Officer. Many members of our senior management have not previously acted in their current capacities for a public company. In addition, certain key members of our
management team were hired recently. Therefore, they will not have been involved with our business and have not worked together as a team for a significant period of time. Consequently, their focus and attention may be diverted while they
familiarize themselves with our business.



39



---

##### Table of Contents

Risks Relating to Owning Our Common Stock

Our executive officers, directors and principal stockholders have the ability to control all matters submitted to our stockholders for approval.

Our executive officers, directors and stockholders who own more than 5% of our outstanding common stock together control approximately 74% of our
outstanding common stock. If these persons were to choose to act together, they would be able to control all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act
together, will control the election of directors and approval of any merger, consolidation, sale of all or substantially all of our assets or other business combination or reorganization. This concentration of voting power could delay or prevent an
acquisition of us on terms that other stockholders may desire. The interests of this group of stockholders may not always coincide with your interests or the interests of other stockholders and they may act in a manner that advances their best
interests and not necessarily those of other stockholders, including obtaining a premium value for their common stock, and might affect the prevailing market price for our common stock.

Our share price may be volatile which may cause the value of our common stock to decline and subject us to securities class action litigation.

The market price of shares of our common stock could be subject to wide fluctuations in response to many risk factors listed in this section, and others
beyond our control, including:



| |  |  | actual or anticipated fluctuations in our financial condition and operating results;
| | - |  | ------------------------------------------------------------------------------------



| |  |  | status and/or results of our clinical trials;
| | - |  | ---------------------------------------------



| |  |  | results of clinical trials of our competitors products;
| | - |  | --------------------------------------------------------



| |  |  | regulatory actions with respect to our products or our competitors products;
| | - |  | -----------------------------------------------------------------------------



| |  |  | actions and decisions by our collaborators or partners, including AstraZeneca;
| | - |  | ------------------------------------------------------------------------------



| |  |  | actual or anticipated changes in our growth rate relative to our competitors;
| | - |  | -----------------------------------------------------------------------------



| |  |  | actual or anticipated fluctuations in our competitors operating results or changes in their growth rate;
| | - |  | ---------------------------------------------------------------------------------------------------------



| |  |  | competition from existing products, new products or generics that may emerge;
| | - |  | -----------------------------------------------------------------------------



| |  |  | issuance of new or updated research or reports by securities analysts;
| | - |  | ----------------------------------------------------------------------



| |  |  | fluctuations in the valuation of companies perceived by investors to be comparable to us;
| | - |  | -----------------------------------------------------------------------------------------



| |  |  | share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;
| | - |  | -----------------------------------------------------------------------------------------------------



| |  |  | market conditions for biopharmaceutical stocks in general; and
| | - |  | --------------------------------------------------------------



| |  |  | general economic and market conditions.
| | - |  | ---------------------------------------

As widely reported, financial markets in the United States, Europe and Asia have been experiencing extreme disruption in recent months, including, among other things, extreme volatility in security prices, severely diminished liquidity and
credit availability, rating downgrades of certain investments and declining valuations of others. Governments have taken unprecedented actions intended to address extreme market conditions that include severely restricted credit and declines in real
estate values. Fluctuations in the market prices of many equity securities often have been unrelated or disproportionate to the operating performance of those companies. These broad market and industry fluctuations, as well as general economic,
political and market conditions such as recessions, interest rate changes or international currency fluctuations, may negatively impact the market price of shares of our common stock.

If securities or industry analysts do not publish research or reports about our business, or publish negative reports about our business, our stock price and trading volume could decline.

The trading market for our common stock depends on the research and reports that securities or industry analysts publish about us or our business. We do
not have any control over these analysts. If one or more of the analysts who cover us downgrade our stock or change their opinion of our stock, our stock price would likely decline. If one or more of these analysts cease coverage of our company or
fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our stock price or trading volume to decline.



40



---

##### Table of Contents

Future sales of our common stock may cause our stock price to decline.

Persons who were our stockholders prior to the sale of shares in our IPO continue to hold a substantial number of shares of our common stock that they
are now able to sell in the public market. Significant portions of these shares are held by a small number of stockholders. Sales by our current stockholders of a substantial number of shares, or the expectation that such sales may occur, could
significantly reduce the market price of our common stock. Moreover, the holders of a substantial number of shares of common stock may have rights, subject to certain conditions, to require us to file registration statements to permit the resale of
their shares in the public market or to include their shares in registration statements that we may file for ourselves or other stockholders.

We have also registered or plan to register all common stock that we may issue under our employee benefits plans. As a result, these shares can be freely sold in the public market upon issuance, subject to restrictions under the securities
laws. In addition, our directors and executive officers may establish programmed selling plans under Rule 10b5-1 of the Exchange Act for the purpose of effecting sales of our common stock. If any of these events cause a large number of our
shares to be sold in the public market, the sales could reduce the trading price of our common stock and impede our ability to raise future capital.

We
will continue to incur significant increased costs as a result of operating as a public company.

As a public company, we will continue
to incur significant legal, accounting and other expenses that we did not incur as a private company. For example, we must use additional internal controls and disclosure controls and procedures, as required by Section 404 of the Sarbanes-Oxley
Act of 2002. Our testing, or the subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses. Our compliance with
Section 404 will require that we incur substantial accounting expense and expend significant management efforts. In addition, we will continue to bear all of the internal and external costs of preparing and distributing periodic public reports
in compliance with our obligations under the securities laws.

Changing laws, regulations and standards relating to corporate governance
and public disclosure, including the Sarbanes-Oxley Act of 2002 and related regulations implemented by the Securities and Exchange Commission and The Nasdaq Global Market, are creating uncertainty for public companies, increasing legal and financial
compliance costs and making some activities more time consuming. We are currently evaluating and monitoring developments with respect to new and proposed rules and cannot predict or estimate the amount of additional costs we may incur or the timing
of such costs. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by
regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We will continue to invest resources to comply with
evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of managements time and attention from potentially revenue-generating activities to compliance
activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to practice, regulatory authorities may initiate legal proceedings against
us and our business may be harmed.

Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may
be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.

Provisions in our amended and restated certificate of incorporation and our bylaws may delay or prevent an acquisition of us. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our
current management by making it more difficult for stockholders to replace members of our board of directors, who are responsible for appointing the members of our management team. In addition, because we are incorporated in Delaware, we are
governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits, with some exceptions, stockholders owning in excess of 15% of our outstanding voting stock from merging or combining with us. Finally, our
charter documents establish advanced notice requirements for nominations for election to our board of directors and for proposing matters that can be acted upon at stockholder meetings. Although we believe these provisions together provide for an
opportunity to receive higher bids by requiring potential acquirers to negotiate with our board of directors, they would apply even if the offer may be considered beneficial by some stockholders.

We have never paid dividends on our common stock, and because we do not anticipate paying any cash dividends in the foreseeable future, capital appreciation, if any,
of our common stock will be your sole source of gain on an investment in our stock.

We have never paid cash dividends on our common
stock and we currently intend to retain our cash and future earnings, if any, to fund the development and growth of our business. We do not anticipate paying any cash dividends on our common stock in the foreseeable future. As a result, capital
appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.



41



---

##### Table of Contents

We may become involved in securities class action litigation that could divert managements attention and harm
our business.

The stock markets have from time to time experienced significant price and volume fluctuations that have affected the
market prices for the common stock of biotechnology and biopharmaceutical companies. These broad market fluctuations may cause the market price of our common stock to decline. In the past, securities class action litigation has often been brought
against a company following a decline in the market price of its securities. This risk is especially relevant for us because biotechnology and biopharmaceutical companies have experienced significant stock price volatility in recent years. We may
become involved in this type of litigation in the future. Litigation often is expensive and diverts managements attention and resources, which could adversely affect our business



|ITEM 6. | EXHIBITS
|------- | --------



|            |  |                                                                                                                                                                                                                            
|----------- |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|Exhibit No. |  | Description                                                                                                                                                                                                                
|3.1         |  | Amended and Restated Certificate of Incorporation of the Registrant (filed as Exhibit 3.1 to the Registrants Quarterly Report on Form 10-Q for the quarter ended September 30, 2007 and
incorporated herein by reference).
|            | 
|3.2         |  | Amended and Restated Bylaws of the Registrant (filed as Exhibit 3.2 to the Registrants Quarterly Report on Form 10-Q for the quarter ended September 30, 2007 and incorporated
herein by reference).                      
|            | 
|4.1         |  | Specimen Stock Certificate (filed as Exhibit 4.1 to the Registrants Registration Statement on Form S-1-A (File No. 333-143823), filed on September 20, 2007, and incorporated
herein by reference).                       
|            | 
|10.1#       |  | Severance Agreement dated March 19, 2009, between Timothy S. Nelson and the Registrant.                                                                                                                                    
|            | 
|31.1        |  | Certification of Principal Executive Officer Required Under Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.                                                                              
|            | 
|31.2        |  | Certification of Principal Financial Officer Required Under Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.                                                                              
|            | 
|32.1        |  | Certification of Principal Executive Officer and Principal Financial Officer Required Under Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C.
§1350.                                        



|# | Indicates management contract or compensatory plan.
|- | ---------------------------------------------------



42



---

##### Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: May 8, 2009



MAP PHARMACEUTICALS, INC.By:

/s/    TIMOTHY S. NELSONTimothy S. Nelson President and Chief Executive Officer (Principal Executive Officer)By:

/s/    CHRISTOPHER Y. CHAIChristopher Y. Chai Chief Financial Officer (Principal Financial Officer)




43